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CHARACTERIZATION OF A MICRORNA HARBORING INTRON FOR PRE-
MRNA SPLICING AND MICRORNA PROCESSING 
    
    NEHA AGGARWAL 
            ABSTRACT 
 
 Nuclear pre-mRNA splicing is an important step in eukaryotic RNA processing 
and can yield a variety of transcripts. Further, it is known that nuclear pre-mRNA introns 
are of two types, U2-dependent and U12-dependent. Recently discovered, microRNAs 
(miRNA) are short, endogenous, 20-22 nucleotide long, non-coding RNA molecules that 
base pair with target mRNAs to modulate translation. Current evidence suggests that 
processing of intronic miRNA does not affect the splicing. Since, intronic miRNAs are 
involved in essential cellular processes, we surmised if splice sites of miRNA coding 
introns are flexible to support productive precursor and mature miRNA processing.  
 We constructed a minigene reporter consisting exons 26-29 including introns 
from MYH6 gene and an intronic miRNA, miR-208 harbored in intron 27. Using in vivo 
and in vitro methods, we examined splicing of MYH6 intron 27 and processing of miR-
208. The predicted stem-loop structure of miR-208 and the 5’ splice site of the intron 27 
were mutated. Stem-loop mutations had no recordable splicing defect of intron 27. The 
5’SS mutant activated a cryptic splicing event using a sub-optimal splice site located 50 
nucleotides upstream of wild-type splice site. Interestingly, conversion of U2-type 5' 
splice site to consensus U12-type 5' splice site did not affect in vivo splicing of the intron, 
suggesting potential conversion of intron to U12-type, albeit without a consensus U12-
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type branch site sequence. However, miRNA processing was affected as established by in 
vitro splicing assay and qRT-PCR analysis of miR-208. 
 We mutated nucleotides from position 3 to 7 in intron 27 to study if changes in 
splice site will allow miRNA processing to occur and if splicing will also be affected. 
Our data indicates significant changes in spliced phenotype as well as in miR-208 
expression level. 
 Since, all known intronic miRNAs are harbored in U2-dependent introns of 
mammalian genes, we wanted to study if miRNA processing will be compatible with 
U12-dependent intron. With this aim, we incorporated miR-208 in a U12-dependent 
intron. However, it appears that spliceosome and microprocessor cannot act together in a 
U12-dependent intron. This is first time that a miRNA has been incorporated in a U12-
dependent intron to study its processing and also if splice sites are plastic for miRNA 
processing.  
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CHAPTER I 
 
        INTRODUCTION 
 
 
1.1 Gene Expression  
The “central dogma” of developmental biology holds that growth and development 
is governed by regulated changes in gene expression. Gene expression involves 
transcription of DNA (genes) to RNA and then translation from RNA to proteins that 
directly affect cellular functions. Both transcription and translation processes are the basic 
fundamentals of molecular biology and both processes are strictly regulated at various steps 
(Hartwell et al, 2004). This regulation at different levels and stages in a cell leads to a 
differential expression and hence to different cell and tissue types.  
Gene expression is influenced by a number of cellular processes, such as 
transcriptional regulation, RNA processing, compartmentalization, translational regulation 
etc (Figure 1). Each eukaryotic gene has its own promoter and its transcription is regulated 
by transcriptional activators or transcription factors. Eukaryotic genes also have one or 
more enhancers generally upstream of the promoter. The promoter is responsible for 
initiating low levels of transcription and determining the transcription start site, enhancers 
are responsible for increasing ("enhancing") transcription levels, and they are also 
responsible for regulating cell or tissue-specific transcription.aaaaaaaaaaaaaaaaaaaaaaaaaaa 
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For example, human β globin gene cluster consists of 5 functionally active genes (ε, 
Gγ, Aγ, δ and β genes) expressing at different stages of life, from embryonic to adulthood 
(Li et al, 1990). It has a ~12 kb enhancer region with binding sites for GATA-1, NF-E2, 
AP-1 and some other transcriptional activators. GATA-1 binds at embryonic stage 
(Takahashi et al, 1997), preferentially expressing the ε gene. In fetal DNA, Gγ and Aγ are 
more strongly expressed and in adults, expression is switched to β gene, while the δ gene is 
weakly expressed (Li et al, 2002).  
Histone regulation and chromatin remodeling are also involved in regulation of 
transcription. Chromatin is condensed to inactive form- heterochromatin. Covalent 
modification such as methylations, acetylations, deacetylations etc of histones occurs, 
reducing transcription. Histone Acetyltransferases (HATs) acetylates lysine residues in 
histone proteins, leads to chromatin remodeling as well as making DNA accessible for 
transcription (Grunstein, 1997).  
Most of the gene-expression changes which are involved in development are 
associated with changes in the level of mRNAs and their regulation (Figure 1). RNA 
polymerase II (RNA pol II) transcribes majority of protein-coding genes. The pre-mRNA 
synthesized by RNA pol II is processed before it can be translated. RNA processing 
involves 5’ capping, 3’ modification by addition of a 3' poly (A) tail, and intron splicing 
(Proudfoot et al, 2002; Shatkin and Manley, 2000; Staley and Guthrie, 1998). If pre-mRNA 
is capped and polyadenylated, it would be transported to the cytoplasm for translation 
otherwise it would be retained in the nucleus for degradation. Introns are spliced in the 
nucleus by formation of a series of dynamic complexes governing introns to be spliced 
(Moore et al, 1993). This process of splicing affects the function of the protein produced. 
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Some genes have exons that might be spliced, producing a different transcript and a 
functionally different protein for example; the calcitonin gene produces calcitonin hormone 
in parafollicular cells of thyroid (Copp and Cheney, 1962; Hirsch et al, 1963) and a 
neurotransmitter (CGRP) in neurons (Brian et al, 1985). This process is called alternative 
splicing and is now known to be involved in a number of diseases.  
mRNAs from different genes have their approximate lifespan encoded in them. The 
information for lifespan is found in the 3' UTR. The sequence AUUUA, when found in the 
3' UTR, is a signal for early degradation and hence a short lifetime (Chen et al, 2001). The 
more times this sequence is 
present, the shorter the 
lifespan of the mRNA. 
mRNA is also 
regulated at translational level. 
Translation in eukaryotes is 
divided into three stages (i) 
initiation (governed by 
initiation factors, eIFs), (ii) 
elongation (governed by 
elongation factors, eEFs) and 
Figure 1: Levels of gene 
expression control: 
Gene expression is 
regulated at various steps 
during transcription as 
well as translational 
processes.  
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(iii) termination (governed by release factors). Translational regulation is exerted mostly at 
the first stage i.e. initiation, where the AUG start codon (sometimes GUG) is identified. It 
is generally regulated by eIF2 or eIF4. 
 Recently, it has been shown that RNA pol II is involved in transcription of 
microRNAs, a novel class of small RNA molecules regulating translation (discussed in 
detail in section 2.3). These are small RNAs which modulate translation, mRNA 
degradation and perhaps other processes. Depending upon complementarily of miRNA 
with the 3’UTR of mRNA transcript, mRNA transcript is either degraded or translation is 
inhibited.  
 
1.2 Nuclear Precursor mRNA (pre-mRNA) Splicing 
 Pre-mRNA splicing involves removal of intervening introns and joining of exons 
forming a mature mRNA. This process appears to occur co-transcriptionally and is an 
essential step in RNA processing. When “interrupted” gene produces primary transcription 
product a heterogeneous nuclear RNA molecule (pre-mRNA), both exons and introns are 
represented. Introns, however, are removed from the primary transcript during the 
processing of pre- mRNA in specific splicing reactions. Splicing is usually constitutive, 
which means that all exons are joined together in the order in which they occur in the 
heterogeneous nuclear RNA (Sharp, 1985). In many genes, however, alternative splicing 
has also been observed, in which exons may be combined in some other way. It is a process 
by which certain exons are skipped and hence the mature mRNA formed is different. This 
leads to formation of different proteins. Alternative splicing is another mechanism by 
which a high degree of diversity and variance can be achieved. Alternative splicing is an 
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important aspect of gene regulation and about 75% of human genes encode pre-mRNAs 
that are alternatively spliced. Numerous diseases are associated with alternative splicing 
and splicing isoforms. Additionally, the proteins encoded by alternative isoforms of a 
particular gene have distinct biological functions (Black, 2003). 
 
1.2.1 Intron: Types, Sequence Conservation and Splicing   
 After the discovery of split genes in 1977, conserved sequences at both ends of 
introns were recognized. These sites are called 5’ splice site and 3’ splice site respectively. 
Another conserved sequence called the branch point region is located within the intron. It is 
usually 20–40 nucleotides upstream of the 3’ splice site. The branch point is almost always 
an adenosine and can rarely be guanine. The sequences at intron ends were GT at the 5’ 
splice site and AG at the 3’ splice site and led to formulation of GT-AG rule (Breathnach et 
al, 1978). This rule holds true in most cases but a number of exceptions to this have been 
found. For example, GC is found at 5’ splice site in case of intron 7 of Human laminin α-4 
(LAMA4) gene (Richards et al, 1997). After about 10 years, it was found that intron F of 
the gene encoding human P120, a proliferating cell nucleolar antigen, and intron 7 of the 
gene encoding human CMP, a cartilage matrix protein have AT and AC at the 5’ and 3’ 
intron ends respectively, instead of GT and AG (Jackson, 1991). Later on, intron 6 of the 
gene encoding Rep-3, a DNA repair protein, and intron 2 of the gene encoding Prospero, a 
Drosophila melanogaster homeodomain transcription factor were shown to have AT-AC 
ends (Hall and Padgett, 1994). It was also shown that AT-AC introns have highly 
conserved 5’ splice site and presumptive branch site sequence elements that are not present 
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in the GT-AC introns, namely, ATATCCTY and CCTTRAY, respectively (Hall and 
Padgett, 1994). 
 The splice sites and branch point region interact with specific RNA and protein 
factors to engage the spliceosome.  The spliceosome is formed by small nuclear RNAs 
(snRNAs) and a number of protein constituents called ribonuclear proteins (RNPs). 
snRNAs and RNPs are together called snRNPs (or snurps). Spliceosome is a dynamic 
complex structure which undergoes rearrangements and finally leading to catalysis 
(Konarska and Sharp, 1987). 
 
  
 
 
 
 
 
 
    Table 1: snRNAs involved in Splicing   
 
 Depending on the conserved sequences in an intron, two spliceosomal systems are 
known to exist in a eukaryotic system. Both the systems recognize 5’splice site, branch 
point sequence and 3’ splice site flanking the intron in a gene. However, the conserved 
consensus sequences recognized are different. But the chemistry involved in splicing 
through both pathways is same. Majority of introns are spliced by U2-dependent pathway 
Major (U2-dependent) 
Spliceosome 
Minor (U12-dependent) 
Spliceosome 
            U1            U11 
            U2            U12 
            U4            U4atac 
            U5            U5 
            U6            U6atac 
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(major pathway) involving U1, U2, U4, U5 and U6 snRNAs (Table 1) (Tycowski et al, 
2006). Generally GT-AC introns and GC-AG introns are splices by major pathway 
however, some exceptions exist (Dietrich et al, 1997). AT-AC introns are spliced by the 
U12-dependent pathway (minor pathway) involving U11, U12, U4atac, U5 and U6atac 
snRNAs (Table 1) (Hall and Padgett, 1996; Tarn and Steitz, 1996 a, b).  
           
1.2.2 Process of Splicing  
Splicing occurs by formation of a large spliceosomal complex and involves two 
trans-esterification reactions. The splicing mechanism involves 2 steps: (i) cleavage of the 
5′ exon–intron phosphodiester bond and formation of a new 2′–5′ bond resulting in an 
intron lariat and (ii) exon ligation. In the first step, the branch point adenosine attacks the 5’ 
splice site, breaking the 
phosphodiester bond and 
simultaneously forming a 2’-5’ 
phosphodiester linkage between the branch point and the 5’ terminal nucleotide of the 
intron. The products of the first reaction are free 5’ exon and 3’ exon bound to lariat intron. 
Figure 2: Mechanism of 
RNA splicing: Step 1 shows 
the nucleophilic attack of 
branch point Adenosine on 
phosphate of 5’ exon. Second 
step shows the attack of 5’ 
exon at 3’ exon bound to 
lariat intermediate and finally 
the formation of lariat 
intermediate and spliced 
exons (Sperling et al, 2008) 
Step 1 
Step 2  
8 
 
After a conformational change within the spliceosome, the second step takes place. Here, 
the newly released 3’ hydroxyl of the 5’ exon, created by the first step, attacks the 3’ splice 
junction, breaking that phosphodiester bond while forming a new phosphodiester bond 
between the 5’exon and 3’ exon (Sperling et al, 2008). The products of the second step are 
ligated exons and the free 
intron, released in the form 
of a lariat intermediate 
(Figure 2). These reactions 
involve rearrangement of 
snRNPs and formation of 
spliceosome. 
Spliceosome 
formation is a complex 
process in which snRNAs 
and protein components of 
snRNPs are sequentially 
loaded on the intron to be 
spliced (Nilsen, TW, 1998; 
Will and Luhrmann, 2001, 
2006). E complex is the 
first to be formed when U1 
binds to the GU sequence 
at the 5' splice site (Zhuang 
Figure 3: Major and minor spliceosomal pathways: 
Consensus 5’ splice site, branch site and 3’ splice site are 
shown for U2 and U12-dependent introns in the upper 
panel. The formation of splicing complexes at various 
stages during the process of splicing are shown in the 
lower panel (Will and Luhrman, 2005). 
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and Weiner, 1986), along with accessory proteins/enzymes such as U2AF (Figure 3). In 
next step, U2 binds to the branch site; this is called the A Complex (Wu and Manley, 
1989). A stable association of U2 snRNA with branch site requires ATP to form the 
prespliceosome. B complex is formed following A complex, by the binding of U5/U4/U6 
tri-snRNP (Konarska and Sharp, 1987). The U5 snRNA binds exons at the 5' splice site and 
U6 snRNA binds to U2 with release of U1 snRNA. Then, U5 shifts from exon to intron and 
U6 binds at the 5' splice site by RNA: RNA interactions (Madhani and Guthrie, 1994). For 
the C complex formation, U6 and U2 catalyze trans-esterification reaction and U4 is 
released from the complex (Lewis and Seraphin, 1993). In next step, with U2, U5 and U6 
still bound, exons are spliced (Nilsen, 1998; Staley and Guthrie, 1998). The final products 
after splicing are spliced exons and lariat intron. Snurps are recycled again used for the 
next round of splicing (Moore et al, 1993). 
 snRNAs involved in U12-dependent pathway are functional analogs of their U2 
dependent counterparts. U11 is a functional analogue of U1 snRNA, U12 of U2, U4atac of 
U4 and U6atac of U6. U5 snRNA is common to both the pathways. There are a few 
differences in splicing by minor spliceosomal pathway (Figure 3). In case of minor 
pathway, U11/U12 di-snRNP is formed and binds to 5’ splice site and branchpoint 
adenosine resulting in formation of A complex. U4atac/U5/U6atac tri-snRNP then binds 
the intron forming B complex (Tarn and Steitz, 1996(b)). Transesterification reactions for 
U12-dependent pathway are similar to U2-dependent pathway (Nilsen, 1996).  
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1.2.3 Methods to Study pre-mRNA Splicing 
 Pre-mRNA splicing is generally studied by two approaches, in vivo and in vitro 
methods. These studies have demonstrated the roles of sequence elements in the pre-
mRNA and the snRNAs in various interactions and the stepwise assembly of the 
spliceosome. The in vivo approach involves transient transfection of wild-type or mutant 
minigenes and then analyzing the spliced variants by RT-PCR method. For in vivo studies, 
a suppressor system is developed in which few mutations are introduced in minigene and 
compensatory base changes in snRNAs are made, allowing minigene to splice as good as 
wild type. It is known that the 5’ end of U1 snRNA and the intronic 5’ splice site interact 
via base pairing (Zhuang and Weiner, 1986; Siliciano and Guthrie, 1988). For major 
pathway, a compensatory base change in U1 snRNA can suppress 5’ splice site mutation 
(Zhuang and Weiner, 1986), allowing splicing to occur as wild type. In case of AT-AC pre-
mRNA splicing (minor splicing), suppressor assay system has also been established. In an 
AT-AC intron, it has been shown that CC at 5th and 6th position in the conserved 5’ splice 
site sequence, ATATCCTY, are absolutely necessary for splicing to occur by the U12-
dependent pathway (Hall and Padgett, 1996; Kolossova and Padgett, 1997; Incorvaia and 
Padgett, 1998). Suppressor AT-AC snRNAs can be cotransfected with AT-AC intron 
mutants to study base pairing interactions between intron and snRNAs.  
 An in vitro splicing method involves splicing of a pre-mRNA transcript in presence 
of nuclear extract. In an in vitro transcribed mRNA transcript is called substrate which 
upon in vitro splicing reaction leads to formation of free lariat intermediate, spliced exons, 
free 5’ exon, lariat intermediate with 3’ exon and all these products can be detected on the 
gel. The in vitro systems for AT-AC pre-mRNA splicing make possible to study the 
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biochemical mechanisms of the reaction. In vitro splicing of has been established for both 
U2-dependent pathway (Moore et al, 1993) and U12-dependent pathway (Tarn and Steitz, 
1996 a). Model minigene system for U2-dependent pathway is human adenovirus-2 gene 
and for U12-dependent pathway is intron F of p120 gene. Both U2-dependent and U12-
dependent splicing occurs in two steps involving trans-esterification reactions and the 
results for splicing are similar in both in vitro splicing systems. 
 Both in vivo and in vitro methods have certain advantages and disadvantages. 
Almost every construct transfected in cells splices upon transfection in contrast to in vitro 
splicing methods where the splicing ability is limited. Utilizing the in vivo system, different 
cell lines can be tested. However, in vivo splicing is prone to indirect effects since intact 
cells are used. Using the in vitro approach, we can differentiate whether splicing occurs by 
major (U2-dependent) or minor pathway (U12-dependent) by blocking one or more 
snRNAs. This inactivation of snRNAs is achieved using 2’O-methyl oligos. For blocking 
U2-dependent splicing, inactivation of U2 snRNAs in the nuclear extract is required to 
detect splicing. However, inactivation of U2 snRNA in addition to U12 snRNA is required 
to block the U12-dependent splicing (Tarn and Steitz, 1996 a). It is believed that since, U2 
is about a hundred times more abundant than U12, U2 competes with U12 for binding to 
the AT-AC branch site (Montzka and Steitz, 1988). Another advantage of the in vitro 
system is enabling to study the kinetics of splicing reaction since an in vitro reaction can be 
stopped at different time points and studied for complex formation. Also different snRNAs 
can be blocked (using 2’O-methyl oligo) and intermediate products can be studied, giving 
insight on the process. 
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1.3 MicroRNAs 
MicroRNAs (miRNAs) are short, endogenous, 20-22 nucleotide long, non-coding 
RNA molecules that can regulate gene expression by base pairing with target mRNAs (Lee 
et al, 1993; Lee and Ambros, 2001; Lagos-Quintana et al, 2001; Kim, 2005; Kim and Nam, 
2006). The founding microRNA lin-4 was discovered more than 25 years ago in the 
nematode Caenorhabditis elegans (Lee et al, 1993). Large numbers of miRNAs have been 
identified since then, making it one of the largest growing fields in the RNA world. To 
date, more than 10884 mature miRNAs have been annotated and 721 of these are human 
microRNAs. They are known to exist in 115 different species, from viruses, fungi to plants 
and vertebrates (mirBase, 14th release; Griffiths-Jones, 2008). MiRNAs are 
computationally found across the genome and then they are confirmed experimentally by 
cloning (Bentwich, 2005). Targets for some of miRNAs are also found computaionally first 
and later on confirmed experimentally (Bentwich, 2005). Many miRNAs are conserved 
across the species indiacting their evolutionary significance. MiRNAs are known to have 
important functions in cellular biology for example; miR 134 is involved in embryonic 
stem cell differentiation (Tay et al, 2008), miR 17-92 cluster in adipogenesis (Wang et al, 
2008) and in cell proliferation and cancer as well (Hayashita et al, 2005). miRNA 
involvement is also implicated in a number of diseases such as, miR 9 and miR 223 for 
ovarian cancer (Laios et al, 2008), miR 375 for Diabetes (Poy et al, 2004, 2009).  
 
1.3.1 miRNA Biogenesis  
 MiRNA biogenesis refers to the processing microRNA from primary transcript to 
mature form (Figure 4). Majority of miRNAs are transcribed by RNA polymerase II 
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(Cullen et al, 2004; Lee et al, 2004; Lee et al, 2002) and some through RNA polymerase III 
(Borchert et al, 2006). The transcript formed is called as primary miRNA and has a stem-
loop structure of about 125 nucleotides. These are processed in a number of steps in both, 
nucleus and cytoplasm to yield 
mature miRNA. In nucleus, pri-
miRNA is excised by Drosha, 
an RNase III-type enzyme (Lee 
et al, 2003). Drosha functions as 
a large protein complex called 
Microprocessor complex that 
contains DGCR8/Pasha as well 
as several splicing factors. 
Cleavage of pri-miRNAs by the 
microprocessor complex 
(Drosha) results in the 
production of shorter, stem-
loop-shaped RNAs called 
precursor miR (pre-miR). These RNAs are ~70 nucleotides long and are exported to the 
cytoplasm by Exportin 5/Ran-GTP complex (Bohnsack et al, 2004; Yi et al, 2003). In the 
Figure 4: miRNA biogenesis pathway: MiRNA genes are transcribed by RNA 
polymerase II to generate the pri-miRNAs. The initial cropping step by the Drosha-
DGCR8 complex, results in formation of pre-miRNA (~70-nt), which is exported by 
the Exp5-Ran complex. Upon export, Dicer participates in the second step of 
processing to produce miRNA duplexes. The duplex is separated and one strand is 
selected as mature miRNAs (http://www.euchromatin.com/ChenCZ01F1.jpg) 
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cytoplasm, pre-miRs are cleaved by the cytoplasmic RNase III-type enzyme, Dicer 
(Ketting et al, 2001). The cleavage reaction yields short RNA duplexes and, subsequently 
one strand of each duplex is incorporated into the RNA-induced silencing complex (RISC). 
RISC complex delivers miRNA to its target mRNA through base pairing with the 3’ 
untranslated regions (UTR). If the miRNA is fully complementary to the 3’UTR of target 
mRNA, it leads to mRNA degradation and if it has incomplete complementarity with 
target, it induces translational repression. 
 
1.3.2 Genomic Locations of miRNA 
 Based on genomic location relative to protein-coding gene locus, miRNA can be 
divided into intergenic or intronic miRNAs. Intergenic miRNAs are found in region 
between the two genes. They generally are independent transcription units, and have their 
own promoters, transcript sequences and terminator sequences; such as lin-4 and let-7 
miRNAs from C. elegans (Bartel, 2004; Kim, 2005). On the other hand, intronic miRNAs 
are located in the introns of a protein-coding gene. They do not have their own promoters 
but are transcribed from the promoter of the protein gene (Kim, 2005).  Intronic miRNA is 
similar to the intergenic miRNA, structurally and functionally; difference being in location 
and requirement for RNA polymerase II for transcription for most intronic miRNAs (Cai et 
al, 2004). However, RNA polymerase III has also been shown to transcribe miRNAs from 
repetitive sequences where the human C19MC 5’ Alu function as miRNA promoters 
(Borchert et al, 2006). 
 
 
15 
 
1.3.3 Intronic miRNAs  
Much is known about miRNA biogenesis and the post-transcriptional affects it has 
on protein coding genes, but very less is known about the transcriptional regulation of 
intronic miRNAs. Recently with advances in the field, it was found that about 80% of 
miRNAs are encoded in the intronic regions of protein-encoding or non-coding genes in 
mammals (Rodriguez et al, 2004; Kim and Kim, 2007) and 75% in Xenopus tropicalis 
(Tang and Maxwell, 2008). This also indicates that the miRNA harbored in introns might 
be evolutionarily conserved in vertebrates. It was earlier thought that all miRNAs have 
their own promoter regions but the expression of intronic miRNAs largely coincides with 
that of their host genes (Baskerville and Bartel, 2005). miRNAs are transcribed from their 
host gene promoters and processed post-transcriptionally from the host pre-mRNAs 
(Sikand et al, 2009). According to computational analysis miRNAs may regulate about 
60% of protein encoding genes, suggesting some important, yet undiscovered regulatory 
mechanisms.  
The fact that mature mRNAs and intronic miRNAs are generated from same 
transcript may have some unknown significance. It was shown that the miRNA-containing 
intron is spliced out slower than the other introns (Kim and Kim, 2007) and a model was 
proposed in which Drosha cleaves the pre-miRNA before the intron is spliced out and the 
two RNA fragments, produced by the pre-miRNA cropping from the pre-mRNA, and 
might subsequently be trans-spliced. Recently, Kataoka et al (2009), using in vitro splicing 
assay system have shown that pre-miRNA cropping could occur prior to mRNA splicing. 
Moreover, the presence of miRNA in the intron slowed splicing while increasing pre-
miRNA production. They have also shown a Y-shaped intermediate and a Y shaped intron 
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indicating trans-splicing. Recently, the association of Drosha (microprocessor) and 
spliceosomal snRNPs has been shown using northern blotting analysis (Kataoka et al, 
2009). This indicates there is a cross-talk between the spliceosomal machinery and the 
micro processor which leads to processing if miRNA from the intron as well as splicing of 
the pre-mRNA.  
 
1.4 Model System: Myosin Heavy Chain and miR 208 
Myosin heavy chain (MHC or MYH) genes are expressed in the heart and largely 
regulate cardiac contractility. MHC gene has two isoforms, α and β, which are regulated 
developmentally. β-MHC (MYH7), is the dominant isoform expressed in the embryonic 
heart and slow skeletal muscle whereas α- MHC (MYH 6) is expressed postnatally in the 
heart (Weiss and Leinwand, 1996). Thyroid hormone (T3) signaling stimulates α-MHC and 
Figure 5: Representation of MYH6 gene and miR-208: Shown is the location of 
miR-208 in intron 27 of MYH6 gene which is a 24.63 kb long gene. Asterisks show 
the sequence conservation across humans, mouse, rat and dog. Also depicted is the 
proposed stem-loop structure of miR-208 and mature miR-208 (vanRooij et al, 2007) 
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inhibits β-MHC transcription after birth (Morkin, 2000). However, in state of heart disease 
there is a switch in MHC genes from α (fast contracting myosin) to β-MHC (slow, 
embryonic myosin).  
Human α- MHC (MYH 6) gene is 25.63 kb long and has 37 exons. Intron 27 of the 
gene contains a highly conserved miRNA, miR-208a (Figure 5). MYH7 gene is a 23.8 Kb 
long gene having 41 exons and intron 31 harboring miR-208b. miR-208a (referred as miR-
208) and miR-208b are 90% identical sequentially. The sequence alignment of miR-208 a 
stem-loop, proposed stem-loop structure of miR-208 and mature miR-208 sequence are 
shown in Figure 5. miR-208 stem-loop sequence is 90% identical across four species, 
namely human, mouse, rat and dog, and the mature sequence is completely conserved. This 
indicates that miR-208 plays some important functions in heart. miR-208 plays an 
important role in the regulation of β to α switch, cardiac hypertrophy and fibrosis. Mice 
with homozygous deletion of mir-208 are viable but do not upregulate MYH7 expression in 
Figure 6: Regulation of cardiac contractility by miR-208: miR-208 expressed by 
MYH6 negatively regulates THRAP1 expression. miR-208 absence results in 
upregulation of skeletal muscle genes and hence cardiac hypertrophy (vanRooij et al, 
2008). 
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response to cardiac stress; however other stress responsive genes were induced. This 
indicated the role of this tiny miRNA in specifically controlling MYH7 expression.  
miR-208 has a half-life of 14 days and therefore can exert its effects even in the 
absence of MYH6 mRNA expression. miR-208 knockout mice at 2 months of age showed 
expression of skeletal muscle contractile protein genes which otherwise are not expressed 
in the heart. This indicated that miR-208 is expressed with MYH6 to repress the expression 
of skeletal muscle genes in the heart (vanRooij et al, 2007).  
 MYH7 expression is repressed by thyroid hormone signaling and is 
upregulated in hypothyroid state. Hypothyroidism can also be induced by treating mice 
with thyroid hormone inhibitor, propylthiouracil. miR-208 knockout mice treated with 
propylthiouracil were found to be resistant to MYH7 expression upregulation. Thyroid 
hormone receptor (TR) coregulator TR-associated protein 1 (THRAP1) is the strongest 
predicted target of miR-208 which can exert both positive and negative effects on 
transcription (vanRooij et al, 2008). The TR represses MYH7 expression in the adult heart 
through a negative thyroid hormone responsive element. In the absence of miR-208, 
THRAP1 expression increases and hence would repress the MYH7 expression (Figure 6).   
Knowing these facts about miR-208, we were interested in knowing if the miRNA 
processing from the intron and splicing of pre-mRNA are related. Kataoka et al (2009) 
have shown that the processing of miR-330 from intron of EML2 gene occurs prior to 
splicing in vitro and both processes are coupled. If this is true universally, miR-208 is also 
an intronic miRNA; hence it’s processing from the must be coupled to the process of 
splicing. Another question to be answered is miRNA processing dependent on splice sites. 
If the processes of miRNA processing and pre-mRNA splicing are coupled and trans-
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splicing occurs (Kataoka et al, 2009), miR processing could be related to 5’ splice site, 3’ 
site and conserved branch site sequences. Trans-splicing is a common phenomenon in 
nematodes (Nilsen, 1993) and trypanosomes (Sutton and Boothroyd, 1986). Trans-splicing 
has been established in vitro system as well and essentially involves the transfer of a 5' 
exon from a pre-mRNA sequence containing an exon, 5’ splice site and adjacent intron to a 
pre-mRNA transcript with exon, 3' splice site and adjacent intron (Konaraska et al, 1985). 
For introns harboring miRNAs trans-splicing has been predicted, and after the processing 
of miRNA from intron, trans-splicing takes place, hence the splice sites of the intron must 
play an important role in the process. If this is true and splice sites play an important role, 
how flexible or how permissive could the splice sites be to allow miRNA processing and 
pre-mRNA splicing to occur.  
Nearly 97% of the human genome is non-coding DNA and the intron occupies most 
of it. Numerous intronic sequences have been recently found to encode microRNAs 
(miRNAs), responsible for miRNA-mediated gene silencing (Ying and Lin, 2009). Several 
kinds of intronic miRNAs have been identified in C. elegans, mouse, and human cells. 
However, their functions and applications are not clear yet. Till date, intronic miRNAs are 
known to exist only in U2-dependent introns only. This could possibly be due to the 
requirement of RNA polymerase II and spliceosomal components for their biogenesis 
(Ying et al, 2010). An interesting question arises, why is a miRNA not present in a U12-
dependent intron. Is minor spliceosome not compatible with miRNA processing. If a 
miRNA is incorporated in a U12-dependent intron, will it be processed and pre-mRNA 
splicing will also occur. Recently, it was shown that revealed that part of the pre-miRNA 
cofractionated with the spliceosome in glycerol gradient sedimentation experiments 
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(Kataoka et al, 2009. U2, U5, and U6 but not U1 or U4 snRNAs coprecipitated with 
Drosha suggesting that major spliceosome associates with Drosha (microprocessor).  
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    CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Minigene Construction 
 A genomic fragment of α-MHC gene consisting exons 26 through 29 was 
amplified by PCR using primers MYH Xho F 5’-GCCTCGAGGAGAGTTGGCCCG 
GCAG-3’ (forward) and MYH BamH1 R 5’-ACGGGATCCCCTGAAGGTTCTTGTTC-
3’ (reverse). The amplified fragment was ligated into pCDNA 3.1(-) plasmid vector 
(Invitrogen, CA) under Xho1 and Bam H1 restriction enzyme sites, clones were selected 
and verified by sequencing. The resultant plasmid was named MYH-208 WT (WT). 
Splice site mutants and miR mutants were constructed by overlapping PCR using 
following sets of primers and then ligating in pCDNA 3.1 (-) vector. 5’SS mutant was 
constructed with primer 2085’SS F 5’-GAGGCCAACCGGGCTCCAG-3’ (forward) and 
208 5’SS R 5’-CTGGAGCCCGGTTGGCCTC-3’ (reverse); U12 5’SS mutant with 208 
U12 5’SS F primer 5’-GAGGCCAAGTATCCTTCAGATACCC-3’ (forward) and 208 
U125’SS R 5’-GGGTATCTGAAGGATACTTGGCCTC-3’ (reverse); 208 U12BS 
mutant with primer 208 U12BS F 5’-CACACACATCCTTAACCCTCACC-3’ (forward) 
and 208 U12BS R 5’-GGTGAGGGTTAAGGATGTGTGTG-3’ (reverse).
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Primers used for lower helix mutant (LH) were 208 LH F 5’-
CTGTGACGCCGCTCGAAAAGGCCCGGG-3’ (forward) and 208 LH R 5’-
CCCGGGCCTTTTCGAGCGGCGTCACAG-3’ (reverse). Primers used for upper helix 
mutant (UH) were 208 UH F 5’-GGCCCGGGAATATCCTGATGCT-3’ (forward) and 
208 UH R 5’-AGCATCAGGATATTCCCGGGCC-3’ (reverse). PCR-based site-directed 
mutagenesis was performed using Change-IT multiple mutation site directed mutagenesis 
kit (USB) to generate loop mutant (Loop) in WT background using 208 Loop primer 5’-
CCCGGGTTATACCACTACGAGTCGTATAAGACGAG-3’ and MYH CC5/6GG 
mutant was created in 208 U125’SS mutant background using 208 CC/GG primer 5’-
GAGGCCAAGTATGGTTCAG-3’. 
 For in vitro transcription, all the above mentioned mutants were PCR amplified 
using forward primer with T7 promoter sequence, MYH T7BamH1 F 5’-
ATATGGATCCTAATACGACTCACTATAGGGGGAGCAGTACGAGGAGGAGA-3’ 
and MYH Xba1 reverse primer 5’-ACGGTCTAGACGTCCACCATCAAGTCCTCT-3’ 
and cloned between BamH1 and Xba1 sites of pUC19 vector.  
 Point mutants were made using Change-IT multiple mutation site directed 
mutagenesis kit (USB) using the mentioned primers: 5’-CCAAGTAAGCTCC-3’ for 
G3A; 5’-CCAAGTCAGCTCC-3’ for G3C; 5’- CAAGTGCGCTCCA-3’ for A4C;         
5’- CAAGTGGGCTCCA-3’ for A4G; 5’-AAGTGAACTCCAG-3’ for G5A;                 
5’- AAGTGACCTCCAG-3’ for G5C; 5’- AGTGAGGTCCAGA-3’ for C6G;                
5’- AGTGAGTTCCAGA-3’ for C6T; 5’-GTGAGCACCAGAT-3’ for T7A;                  
5’-GTGAGCGCCAGAT-3’ for T7G.  
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p120 minigene construct (p120 WT) was a gift from Richard Padgett, Learner 
Research Institute, Cleveland Clinic Foundation. It has a well characterized U-12 
dependent intron (intron F). p120 CC5/6GG mutant was made by mutating CC5/6GG in 
intron F of p120 WT. For p120-miR208 mutant, site-directed mutagenesis was performed 
using Change-IT multiple mutation site directed mutagenesis kit (USB) to introduce 
Pme1 and Not1 sites in the p120 WT construct in pCB6 vector using 5’-
GAGGAAGGCGGCCGCGAGAGG G-3’ to introduce Not1 site and 5’- 
GAGAGGGGTTTAAACGCCTTAG-3’ primer to introduce Pme1 site. The DNA 
fragment containing pre-miR330 was amplified by PCR from the WT plasmid using 5’-
GAATGCGGCCGCTGAACTCTGGCTGGCCCTGA-3’ (forward) and 5’-
GCATGTTTAAACCACACAGGCTGATCGACGGT-3’ (reverse) and cloned into Pme1 
and Not1 modified p120 WT. Site directed mutagenesis was performed using Change-IT 
multiple mutation site directed mutagenesis kit (USB) and called p120 5’SS mutant with 
primer 5’-GATGGAGCAGGATGAGTTTGCAGGGCAGAG-3’ and second mutant 
called p120 CC5/6GG using 5’-TGGAGCAGGATATGGTTGCAGGGCAGAG-3’. U11 
and U6atac suppressors cloned in pALTER expression vector was a gift from Richard 
Padgett, Learner Research Institute, Cleveland Clinic Foundation.  
 All plasmids were transformed in DH5α competent cells, plated on Ampicillin 
(Amp 100 mg/ml) containing Agar plates. Colonies were picked and grown overnight in 
5ml Luria Broth (LB, Amresco, OH) containing 5 µl Amp (100 mg/ml) at 37 °C. Mini-
preps were done using Zyppy miniprep kit (Zymo Research, CA). Mutations were 
confirmed by sequence analysis and then maxiprep was done using Plasmid Maxi Kit 
(Qiagen, AL).  
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2.2 CHO Cell Maintenance and Transfection 
 CHO cells were cultured in 10 ml complete CHO media containing DMEM-1x with 
4.5 g/l glucose and L-glutamine (CCF, OH), P/S (CCF, OH), 5% FBS (Atlanta Biologicals, 
GA), 1 mM L-proline (Sigma, MO) and 10 mM HEPES (SIGMA, MO). All cells were kept 
in a humidified incubator at an atmosphere of 5% CO2 at 37 °C. 
For transfection, a 100% confluent 100 mm plate was split at 1:8 ratio in 100 mm 
plates using 10 ml complete CHO media. The cells were ~70 % confluent after 24 hrs and 
morphologically healthy for transfection. Cells were transfected using 5 ml complete CHO 
media containing 12 µl polybrene (10 mg/ml Sigma, MO) and 1.2 µg plasmid DNA per 
plate. 9 µg pUC19 was used as carrier and to equalize amount of DNA being added. In wells 
where both U11 suppressor plasmid and U6atac suppressor mutants were transfected 
together, pUC19 vector was omitted. After 8 hrs, media from the wells was aspirated and 
cells were treated with 5 ml of 30 % DMSO (in complete CHO media) and incubated at room 
temperature for 5 minutes. Plates were washed with 5 ml complete CHO media and finally 
replenished with 10 ml CHO media. Cells were cultured at 37 °C in a humidified 5 % CO2 
incubator. The cells were harvested after 36 hours of incubation post-DMSO shock.  
 
2.3 Total RNA Isolation  
 Total RNA isolation from cells growing in monolayer was done by TRIzol 
Method, a modification of the method developed by Chomczynski,P. and Sacchi, N. 
(1987). Briefly, the cells were lysed directly in culture dish by adding 1 ml TRIzol 
(Invitrogen, CA) reagent to each well, transferred to an eppendorf and added 0.2 ml 
Chloroform (Amresco, OH). Samples were centrifuged and aqueous phase was collected. 
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RNA present in aqueous phase was precipitated and washed using Isopropanol (Amresco, 
OH) and 70 % Ethanol (Amresco, OH) respectively. Pellet obtained finally was 
resuspended in DEPC treated water and stored in -80 ºC till further use. The isolated 
RNA was quantitated spectrophotometerically and absorbance was taken at 260 nm and 
280 nm. Integrity of RNA was checked on denaturing 1% MOPS-Agarose gel.  
 
2.4 Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) 
 Reverse transcription was performed using GeneAmp Thermostable rTth Reverse 
Transcriptase RNA PCR Kit (Applied Biosystems, CA) using 0.5 µg total RNA per 
reaction. A master mix was made as per manual but scaling down reaction volume to 10 
µl.  
 For MYH-mir208 stem-loop and splice site mutants, RT was done using vector 
specific RT primer 5’-CAACAGATGGCTGGCAACTA-3’ at 70 °C for 15 min in a 
PTC-100 (Bio-Rad Laboratories, CA) thermal cycler. The reaction was stopped by 
keeping tubes on ice for at least 5 min. PCR was performed using master mix specified in 
the manual scaling down reaction to 40 µl using Exon Junction F primer 5’-
GAGGGCAAGGCGAAGAAC-3’. Amplification was done for 40 cycles consisting of 
denaturation at 95 °C for 1 min, annealing/extension at 55 °C for 1.05 min and a final 
extension at 68 °C for 7 minutes. RT for point mutants was performed using RT primer 
according to user manual (Promega, WI). 
 For p120 minigene, RT was done using p120 mini-gene specific reverse primer E-
7-8-2 primer 5’-CTTCTAAGAACTCCACCAGCTCAGA-3’ at 70 °C for 15 min in a 
PTC-100 (Bio-rad Laboratories, CA) thermal cycler. The reaction was stopped by 
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incubating tubes on ice for at least 5 min. Then PCR was performed using master mix 
specified in the manual scaling down reaction to 40 µl using E-5-6 primer                      
5’-GGCCCGGGAAGCTGCTGCTGGGATC-3’. Amplification was done for 40 cycles 
with denaturation at 95 °C for 1 min, annealing/extension at 60 °C for 1.05 min and a 
final extension at 68 °C for 7 minutes.  
 
2.5 In vivo Splicing Phenotype Analysis for MYH6 miR-208 
Nested PCR was performed using GoTaq PCR core system II (Promega, WI) 
setting up a reaction of 25 µl according to manual provided. Primers used for 
amplification were F2 5’- GGAGCAGTACGAGGAGGAGA-3’ (forward) and R2 5’- 
CGTCCACCATCAAGTCCTCT-3’ (reverse). PCR was done using program “55” 
involving denaturation at 95 °C for 3 min followed by 25 cycles of denaturation at 95 °C 
for 1 min and annealing/extension at 60 °C for 1.05 min final extension at 68 °C for 7 
min. The products were analyzed on 2 % Agarose-1X TBE gels.   
 Nested PCR was performed using GoTaq PCR core system II (Promega, WI) was 
also preformed to check various spliced products with upstream and downstream exons. 
Primers were used in different combinations as indicated. Primers used are indicated as F 
for forward and R for reverse, F1: 5’-GGAAAAGGAGGCGCTAATCT-3’; F2: 5’-GG 
AGCAGTACGAGGAGGAGA-3’; F3: 5’-GGCTGTTAATGCCAAGTGCT-3’; R1: 5’-
GCGTCCGTCTCATACTTGGT-3’; R2: 5’-CGTCCACCATCAAGTCCTCT-3’; R3:  
5’-TCGTAGGCGTTCTTGAGCTT-3’. PCR amplification was done using PTC-100 
(Bio-Rad, CA) thermal cycler. PCR program used was denaturation at 95 °C for 2 min, 
followed by 36 cycles of denaturation at 95 °C for 1 min, annealing at 55 °C for 1 min, 
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extension at 72 °C for 1 minute and a final extension at 72 °C for 5 min. PCR products 
were checked on a 2 % Agarose gel.  
 
2.6 In vivo Splicing Phenotype Analysis for p120 Minigene 
 Nested PCR was performed using Hi Fidelity PCR Kit (Roche, IN) setting up a 
reaction of 25µl according to manual provided. Primers used for amplification were E6 
long 5’- TTGTGCTGCCCCCTGCTGGGGAGATG-3’ (forward) and E7 long 5’- 
TGAGCCCCAAAATCAGCAGAATTCC-3’ (reverse). PCR was done using 
amplification program involving denaturation at 95 °C for 3 min followed by 25 cycles of 
denaturation at 95 °C for 1 min and annealing/extension at 60 °C for 1.05 min, final 
extension at 68 °C for 7 min. The products were analyzed on 3 % (2 % Agarose: 1 % 
NuSieve) Agarose-1X TBE gels. 
 
2.7 In vitro Transcription Assay 
 Reaction was set up at room temperature using maxiscript kit (Ambion, TX). A 
50 µl reaction was set up and reagents were added in following order: 12.5 µl Nuclease-
free water, 5 µl 10X Transcription Buffer (with DTT), 2.5 µl 10 mM ATP, 2.5 µl 1 mM 
UTP, 2.5 µl 10 mM CTP, 2.5 µl 1 mM GTP, 2.5 µl 10 mM m7G(5’)ppp(5’)G cap analog 
(Ambion, TX), 10 µl (2 µg) linearized DNA template, 5 µl [α-32P] UTP 800 Ci/mmol 
(10 mCi/mL- MP Biomedicals, OH) and finally 5 µl T7 RNA Polymerase (10 U/µl). All 
reactions were incubated at 37 °C for 2 hrs. Then, 2 µl RNase-free DNase I (2 U/µl) was 
added to the reaction mixture to remove the DNA template, mixed thoroughly, and 
incubated for 20 min at 37 °C. Gel loading Buffer II (Ambion, TX) was added to 
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samples. Samples were loaded on pre-electrophoresed 8 M Urea 5% polyacrylamide gel. 
Covered gel with saran wrap and exposed it to phosphor imager screen for about 1 min 
and scanned and extracted the band. To elute RNA from gel, added 400 µl G50 buffer 
(1.7 g Sodium Acetate, 0.5 ml 2 M Tris pH 7.5) to the band and eluted overnight on 
rotator at 4 °C. Next day, collected supernatant in a fresh tube, 900 µl ethanol and 40 µg 
glycogen (Roche, IN) were added and precipitated RNA at -20 °C overnight. Following 
day, samples were spun at 13000 rpm 20 min and pellet obtained was resuspended in 
nuclease-free H2O and store at -20 °C in a β-blocker.  
 Century Markers (Ambion, TX) were transcribed as per manual guidelines. 
Briefly, reaction was set using 6 µL Nuclease-free water, 2 µL 10X Transcription Buffer 
(with DTT), 1 µL 10 mM ATP, 1 µL 10 mM CTP, 5 µL 10 mM GTP, 1 µL 1 mM UTP, 1 
µL 0.5 µg RNA Century Marker Template Set, 2 µL [α-32P] UTP 800 Ci/mmol (10 
mCi/mL in aqueous solution) and 1 µL T7 RNA Polymerase (10 U/µL). Reaction mix 
was incubated at 37°C for 1 hr and 1 µL RNase-free DNase I (2 U/µL) was added to the 
reaction to remove the DNA templates, and incubated for an additional 15 min at 37°C. 
The terminated transcription reaction was passed through a G-25 or G-50 
chromatography column to remove unincorporated nucleotides. Counts per minute (cpm) 
were recorded and sample was diluted to 2000 counts/µL.  
 Decade Markers (Ambion, TX) were transcribed as per manual guidelines. 
Briefly, reaction mix was made in a nuclease-free tube using 1 µL Decade Marker RNA 
(100 ng), 6 µL Nuclease-free water, 1 µL 10X Kinase Reaction Buffer, 1 µL [γ–32P] 
ATP and 1 µL T4 Polynucleotide Kinase. Incubated at 37°C for 1 hr. Then 8 µL 
Nuclease-free water and 2 µL 10X Cleavage Reagent were added. Reaction mix was 
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further incubated at room temperature for 5 min. Then 20 µL Gel Loading Buffer II was 
added to stop the reaction. The mixture was heated at 95°C for 5 min before loading on 
the gel. 
 
2.8 In vitro pre-mRNA Splicing in Cell-free Extracts 
 All reactions were set up on ice. Mix1 was made fresh every time and contained 
25 µl ATP/Phosphocreatine/Cordycepin 5’ phosphate mix (60 µl 100mM ATP (Roche, 
IN), 50 µl 0.5 mM Cordycepin 5’ phosphate (Sigma, MO), 100 mM Cordycepin 
5’triphosphate- 15 µl and H2O- 375µl), 6 µl 0.5M Phosphocreatine and 49 µl H2O. To set 
up a 25 µl reaction, added 8.0 µl Mix 1, 1.0 µl RNase inhibitor (SUPERase In- 20 U/µl- 
Ambion, TX), 1 µl 25mM MgCl2, 4 µl nuclease-free H2O, 10 µl nuclear extract and 
finally 1 µl substrate mRNA (P-32 labeled) in an eppendorf. If anti-U2 or anti-U12 2’O-
methyl oligos (Dharmacon, CO) were used, the reactions were incubated at 30 °C for 15 
minutes and then labeled-pre mRNA was added. To block U2 dependent splicing, 8 µM 
anti-U2b oligo was used whose sequence is complementary to U2 nucleotides 27–49 
(Dietrich et al, 1997).  To block U12 dependent splicing 8uM anti-U2b oligo along with 5 
µM anti-U12 oligo (Dharmacon, CO) was used whose sequence was complementary to 
U12 nucleotides 11–28 (Dietrich et al, 1997). All reactions were incubated at 30 °C for 
90 minutes in case of adeno and adeno-miR constructs and 3 hours for reactions 
involving p120 and MYH. Then centrifuged and added 200 µl G50 buffer (1.7g Sodium 
Acetate, 0.5 ml 2M Tris pH 7.5) followed by 5 µl Proteinase K (Roche, IN) and 
incubated the reaction at 42 °C for 20 minutes. Then added 200 µl of phenol/ chloroform 
(Ambion, TX), vortexed 3-4 times and centrifuged at 13000 rpm for 5 minutes at room 
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temperature. Carefully collected the supernatant in another eppendorf and added 200 µl 
chloroform (Amresco, OH), vortexed 3-4 times and centrifuged at 13000 rpm for 5 
minutes at room temperature. Again collected supernatant in a new tube and added 40 µg 
glycogen (Roche, IN) followed by 500 µl ethanol. Samples were kept at -20 °C overnight 
for precipitation. Next day, centrifuged samples at 13000 rpm for 20 minutes at 4 °C and 
pellet obtained was resuspended in 10 µl gel loading buffer II (Ambion, TX). Samples 
were incubated at 95 °C for 2 minutes, immediately chilled on ice and loaded on heated 
Urea-PAGE gel. Gel was run at 15-18W constant power. Gel was dried and exposed to 
phosphor imager screen at least overnight. 
 
2.9 Reverse Transcription and Quantitative Real-Time (qRT) PCR Analysis of 
Mature miRNA Expression 
First strand cDNA was synthesized from 100ng of total RNA using primers 
specific for mature miR-208 and small nucleolar RNA 202 (sno202).The miRNA-
specific primers were obtained from TaqMan MicroRNA Assays (Applied Biosystems 
Foster City, CA). Reagents for cDNA synthesis were obtained from TaqMan MicroRNA 
Reverse Transcription kit (Applied Biosystems, CA). For each sample, a 15µl reverse 
transcription (RT) reaction was set up containing 10ng of total RNA, 1X RT buffer, 1mM 
of dNTP mix, 50 units of MultiScribe reverse trancriptase, 3.8 units of RNase inhibitor 
and 3µl of miRNA-specific RT primer. The reactions were incubated in a thermal cycler 
(Bio-Rad PTC-100) at 16°C for 30 minutes, 42°C for 30 minutes, and 85°C for 5 minutes 
and then held at 4°C. The ‘reverse transcriptase minus’ controls were also synthesized 
under the same conditions. In order to quantify the mature miR-208 and sno202 in each 
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sample, the cDNAs were amplified using TaqMan MicroRNA Assays together with the 
TaqMan 2X Universal PCR Master Mix (Applied Biosystems, CA). Briefly, a 20µl 
reaction was set up containing 1.33µl product from RT reaction, 1µl of 20X TaqMan 
microRNA assay mix (mixture of miRNA-specific forward and reverse primers, and 
miRNA-specific TaqMan MGB probe labeled with FAM fluorescent dye) and 10µl of 
TaqMan 2X Universal PCR Master Mix. These reactions were dispensed into a 96-well 
optical plate and the plate was positioned in 7500 Real-time PCR System (Applied 
Biosystems) under the following conditions: 95°C for 10 minutes followed by 40 cycles 
of 95°C for 15 seconds and 60°C for 1 minute. Three replicates were performed per RT 
reaction together with the ‘reverse transcriptase minus’ and ‘no template’ controls. 
Duplicate PCRs were performed for all the RNA sample. The mean Ct was determined 
from the replicates. Sno202 expression was used as an invariant control. The relative 
expression of each miRNA was calculated as 2-∆Ct where ∆Ct = Ct value of each miRNA 
in a sample – Ct value of sno202 in that sample. All experiments were repeated with 
three and all replicates provided similar results. 
Statistical Analysis  
The statistical analysis of expression levels of miR-208 and was performed using 
the SPSS package.  The index of expression of each miRNA was 2-∆Ct after normalization 
to sno202 expression levels. A student t-test was applied to the samples. Expression 
levels are considered significant if p < 0.5.  
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    CHAPTER III 
   RESULTS and DISCUSSION 
 
3.1 Construction of MYH Minigene Reporter System 
 To study the events of pre-mRNA splicing and miRNA processing, a reporter 
system that could experimentally enable us to study both processes was required. To 
achieve this aim, a minigene reporter was constructed from Myosin Heavy Chain 6 gene 
(MYH6). A 1764 base long fragment (Appendix 2) from exons 26 through 29 was PCR 
amplified from human genomic DNA and cloned between the Xho1 and BamH1 sites of 
pCDNA3.1 (-) under CMV promoter (Appendix 1). Hence, the reporter system consists 
of exons 26 to 29, including introns 26, 27 and 28. Intron 27 of MYH6 gene encodes the 
miRNA, miR-208. miR-208 has been implicated in regulating cardiac hypertrophy and 
myocardial infarction (vanRooij et al, 2007; Callis et al, 2009).  
 A schematic of minigene reporter construct is represented in Figure 7. E 26 to 
E29 correspond to the exons 26, 27, 28 and 29 from the MYH6 gene and I 26 to I 28 
represent the introns 26, 27, 28 respectively. Forward primers designated as F1, F2 and 
F3 are located in exons 26, 27 and 28 respectively and R1, R2 and R3 represents the 
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reverse primers located in exons 27, 28 and 29 respectively (further details Chapter II and 
Appendix). 
 
 
 
 
3.2 Expression of MYH in Mouse Tissues 
 miR-208 is encoded by intron 27 of MYH6 gene and is expressed specifically in 
the heart and tracely in lungs (van Rooij et al, 2007; Callis et al, 2009). It was important 
to know if MYH6 is expressed in 
other tissues or is it tissue-specific as 
miR-208. We performed RT-PCR on 
RNA isolated from mouse organs, 
heart, kidney, liver, brain and lungs. 
GAPDH was used as an internal 
control. Our data shows that MYH6 
expresses in lungs, heart and kidney 
(Figure 8) if PCR amplification is 
done for 30 cycles. Expression of 
MYH6 gene was observed in brain as 
R3 
E 26 E 29 E 28 E 27 
I26 I28       I27 
   miR-208 F1 F3 
F2 
R1 R2 
WT Splicing 
Figure 7: Structure of the minigene reporter construct and location of primers: 
E represent the exons 26-29 and I represent the introns 26-28. Forward primers are 
denoted by F and R represents reverse primers. miR-208 is encoded in the intron 27 
of the minigene construct. Dashed lines show wild-type splicing junctions.   
Figure 8: MYH6 expression in mouse 
organs: RNA was isolated from mouse 
tissues and RT-PCR analysis was done 
using specific primers. Upper panel shows 
results for MYH6 gene expression in 
mouse tissues and lower panel shows 
expression of GAPDH (internal control).  
MYH 
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well if the PCR cycles are increased from 30 to 40. However, MYH6 expression was not 
detected in liver even at 40 cycles. Since the miR-208 expresses only in mouse heart and 
tracely in lungs (van Rooij et al, 2007), its expression is tissue specific. Its expression 
could also be regulated post-transcriptionally, however, any factors involved in miR-208 
processing from intron 27 of MYH6 are not yet known. This experiment also suggested 
us to choose a cell system not derived from heart, kidney, lungs or brain so that there is 
no interference of endogenous MYH6. 
 
3.3 Optimization of Transient Transfection Conditions 
 To study the events of splicing and miRNA processing it was necessary to 
recapitulate the MYH6 splicing and miR-208 processing in an in vivo assayable system. 
To achieve this objective, MYH6 minigene reporter system was constructed (as described 
in Chapter II). MYH WT was transfected in HEK293T cells using lipofectamine at 
concentrations of 0.4 µg, 0.8 µg, 1.0 µg and 1.2 µg per well of a 6-well plate along with 
appropriate controls. Cells were harvested after 36 hours and RNA was isolated using 
Figure 9: Optimization of transient 
transfection conditions:  Minigene 
construct was transfected at different 
concentrations as indicated, RNA was 
isolated 36 hrs post transfection and RT 
using vector backbone primer and PCR 
using F2 and R2 primers which flank miR-
208 containing exons was performed.  
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Trizol. To specifically amplify exogenously transfected MYH6 minigene construct, 
reverse transcription was done using a vector backbone specific primer (RT primer) and 
then PCR was done using F2 and R2 primers located on exons 27 and 28 respectively 
(Figure 7). The PCR product was loaded on a 2% Agarose-1x TBE gel and compared the 
splice variants (desired ~263 bp) with the 100 bp molecular weight ladder (Figure 9). 
Some other non-specific products were observed at ~600 bp and ~1000 bp. When the 
cDNA was cleaned up and purified to remove RT primer, none of the non-specific 
products was observed. The best spliced phenotypes were observed at a concentration of 
B 
Figure 10: Optimization of 
primers sets located on 
MYH6 minigene construct: 
PCR was performed with all 
primers designed and in 
Panel A spliced phenotypes 
and primer sets used for 
amplification are mentioned 
on top. Panel B depicts 
schematics of spliced 
products obtained using all 
combination sets of primers 
in panel A along with their 
sizes. Each box denotes an 
exon. For example, lane 1 in 
Panel A corresponds to 
spliced phenotype obtained 
using primers F1 and R1. 
Schematic of spliced product 
amplified shown in lane 1 is 
represented in panel B, 
product is spliced exons 26 
and 27 and is 261 bp long.  
A 
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1.2 µg transfected in HEK293T cells and this optimized concentration was used for 
further transfections.  
  It was necessary to check if the in vivo splicing takes place from upstream and 
downstream exons as well as the efficiency of MYH minigene reporter construct.  RT-
PCR was performed using the vector specific primer and cDNA was cleaned using DNA 
clean and concentrator kit. PCR amplification was done using appropriate sets of primers 
as represented in Figure 10, panel A. If splicing occurs from the correct splice site 
junctions, products of specific lengths shown in Figure 10, panel B are expected. Since 
F1 primer is located on exon 26 and R1 primer is on exon 27, intron 26 will be spliced 
out and the expected product size is 261 base pairs long (Figure 10, Panels A and B, lane 
1). Similarly, F1 and R2 primers would yield a 418 bp long product by splicing of exons 
26, 27 and 28 (Figure 10, Panel A and B, lane 2). Primers F1 and R3 are located in exons 
26 and 29 respectively and would yield largest product of 590 bp by splicing of exons 26 
to 29 (Figure 10, Panel A and B, lane 3).  F2 and R3 primers would yield a product of 
435 bp, by splicing exons 27 to 29 (Figure 10, Panel A and B, lane 4). Primers F3 and R3 
are located on exons 28 and 29 respectively and yield a spliced product of 252 bp long 
containing exons 28 and 29 (Figure 10, Panel A and B, lane 5). PCR products were 
isolated from the gel and sequenced to identify the spliced junction sequences. The 
sequencing results obtained showed that the PCR products spliced at correct splicing 
junctions. 
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3.4 In vivo Splicing Phenotypes of miRNA Stem-Loop Mutants  
 It has been proposed that RNA-RNA interactions or RNA-protein interactions are 
involved in structure recognition and processing precursor miRNA to mature sequence. 
Lower helix, upper helix and the terminal loop are the required structural regions for the 
miRNA processing to occur (Kim and Kim, 2007). After optimization of the minigene 
system, we wanted to answer specific question- whether miRNA sequence affects pre-
mRNA splicing or not. To answer this question we introduced mutations in the stem-loop 
structure of hsa-miR208 (Figure 11 A).  
 
 
 
 
WT 
Lower Helix 
Mutant 
Figure 11: Structure of predicted hsa-miR-208 stem loop: (A) correspond to 
predicted stem-loop structure and sequence/regions of precursor miR-208. Sequence of 
mature miR-208 is illustrated in green letters. (B)- (D) represent lower helix, upper 
helix and loop mutants of hsa-miR-208. Regions marked with crosses in the mutants 
indicate abolished base pairing interactions whereas extended helix is predicted to 
form in loop mutant. Mutated bases are shown in bold letters. 
 
Upper Helix 
Mutant 
Loop 
Mutant  
38 
 
We introduced non-complementary mutations in the helical regions to disrupt the base 
pairing interactions between 5’ and 3’ end of predicted miRNA stem-loop structure 
(Figure 11, B and C).  These mutants were called the lower helix (LH) or the upper helix 
(UH) mutants. For the loop mutant, base pairing interactions were introduced at the 
terminal loop region and hence formation of an extended helix is predicted (Figure 11 D). 
All splice site mutants along with wild type minigene construct and appropriate controls 
were transfected in CHO cells using polybrene and upon RNA isolation analyzed for 
spliced phenotypes. Wild type (WT) spliced product is 263 bp long if splicing occurs at 
correct splice junctions (Figure 12, lane 2).  Upper helix (UH), lower helix (LH) and 
Loop mutants did not have any effect on splicing and yield product similar to wild-type 
(Figure 12, lanes 3, 4, 5). To verify if these mutants spliced from the wild type splice 
junctions, PCR products were eluted from the gel and sequenced. The analysis of 
sequencing data from the three miR-208 stem-loop mutants obtained showed that splice 
junctions are same as that of the wild-type. This data from the miRNA stem-loop mutants 
indicates that miRNA mutations do not affect splicing in vivo. 
 
 
Figure 12: In vivo splicing 
patterns of miRNA mutants: UH, 
LH and Loop mutants were 
transfected with appropriate 
controls. PCR was performed using 
F2 and R2 primers. PCR products 
were loaded on 2 % Agarose-1X 
TBE gels.  
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3.5 In vitro Splicing Assay for Stem-Loop Mutants 
 There are advantages of using the in vitro system over the in vivo system. Firstly, 
using an in vitro system all intermediate stages and products of splicing and miRNA 
processing can be resolved on the same gel, on the other hand, using in vivo system only 
the final spliced product can be identified. Secondly, one or more snRNAs can be 
blocked at different time points to establish the role of snRNAs in splicing (and miRNA 
processing). Splicing reaction kinetics can be studied and different complexes formed 
during the process of splicing can be identified.   
 A 788 bp region containing exon 27 and exon 28 including the miR-208 
harboring intron 27 was PCR amplified from miRNA stem-loop mutants as well as the 
wild-type and cloned in pUC19 vector under T7 promoter. Plasmid DNA was linearized 
with restriction enzyme, Xba1 and transcribed in vitro as described in Chapter 2. In vitro 
splicing assay was performed in HeLa cell nuclear extracts as described earlier and in 
vitro spliced phenotypes of MYH6 wild-type and miRNA stem-loop mutants were 
analyzed on 8M Urea-8% PAGE gel.  To compare the sizes of the products generated in 
the assay, century (100 bp RNA ladder) and decade markers (10 bp RNA ladder) were 
used (Figure 13, lanes 1 and 12 respectively) since products ranging from 70 bp (pre-
miR-208) to 788 bp (pre-mRNA transcript) were expected. Adeno-viral mRNA with hsa-
miR-208 incorporated in intron was used as control to optimize in vitro splicing reaction 
conditions. Both adeno-viral and MYH6 minigene constructs splice using major 
spliceosomal pathway. Adenoviral construct containing miR-208 in intron was spliced in 
vitro and spliced exons and precursor miR-208 (pre-miR-208) were observed (Figure 13, 
lane 2), indicating that the nuclear extract is sufficient for in vitro splicing to occur. 
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Spliced exons were not observed in adenoviral construct incubated with anti-U2 oligo 
(Figure 13, lane 3). This showed that the anti-U2 oligo could block U2-dependent 
splicing (as its sequence is complementary to U2 nucleotides 27–49 (Dietrich et al, 
1997). Interestingly, blocking splicing did not abolish miRNA processing upto the 
Adeno 
 
Figure 13: In vitro spliced phenotypes of stem loop mutants: Lane 1 shows 
century marker, lane 12 shows decade marker, lanes 2 and 3 show in vitro spliced 
adeno-miR construct. Lanes 4-5, 6-7, 8-9 and 10-11 show in vitro spliced MYH6 
wild-type, UH, LH and Loop mutants respectively. Anti-U2 indicates samples where 
anti-U2 oligo was added to block U2-dependent splicing. Drosha cleaved products 
namely, miR-208 stem-loop, upstream exon to 5’ end of miR and from 3’ end of miR 
to 3’exon were observed as indicated.  
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precursor stage, though the level of pre-miR-208 observed was reduced. Wild-type MYH 
construct appears to be splicing deficit, however precursor microRNA was observed 
(Figure 13, lane 4). Interestingly, two pre-mRNA by-products were also observed 
between 300 and 400 bp. These products appear to be Drosha cleaved products, i.e. the 
region from starting of mRNA to 5’end of pre-miR-208 and 3’ end of pre-miR-208 to the 
end of mRNA (Figure 13) and the length of these products should be 387 bp and 330 bp 
(by analyzing the genomic sequence). However, the identity of these products has not 
been experimentally proven yet. Wild type MYH construct along with anti-U2 oligo 
showed reduced levels of the Drosha cleaved pre-mRNA products as well as the pre-
miR-208 (lane 5). Interestingly, pre-miR-208 along with Drosha cleaved pre-mRNA was 
also not detected in upper helix (UH) and the lower helix (LH) mutants, in the presence 
or absence of anti-U2 oligo (Figure 13, lanes 6-9). In vitro spliced products of loop 
mutant, with and without anti-U2 oligo are shown in lanes 10 and 11. This mutant is also 
splicing deficient as the wild-type and hence spliced products were not observed, 
however Drosha cleaved pre-mRNA products and pre-miRNA in low level were seen.  
 Recently, mRNA splicing and pre-miRNA processing have been detected in an in 
vitro system with HeLa cell nuclear extract using the EML2 gene harboring miR-330 
(Kataoka et al, 2009). The EML2 pre-mRNA was a good substrate for splicing as well as 
miRNA processing in contrast to the MYH6 pre-mRNA. We also performed in vitro 
splicing assay with a 900 bp long (including full exons 27 and 28) MYH6 pre-mRNA 
substrate but observed similar results. We suspect that MYH6 gene might have some key 
cis-regulating elements, upstream of exon 27 or downstream of exon 28, necessary for 
MYH6 pre-mRNA to splice. Kataoka et al (2009) showed that pre-mRNA processing 
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(cropping) occurs prior to pre-mRNA splicing and presence of miRNA in an intron slows 
down the process of pre-mRNA splicing. Similar results were obtained with MYH6 pre-
mRNA where pre-miR-208 could be detected as early as 20 minutes but spliced mRNA 
could not be detected even after 2 hours (Dietrich et al, unpublished). 
 
3.6 In vivo Splicing Phenotypes of MYH6 Intron27 5’splice site Mutants 
 An intron has certain cis-acting elements which are required for splicing, namely, 
5’splice site; branch point, adenosine and the consensus 3’splice site (Figure 14).  These 
cis-elements are required for binding to specific snRNAs and other factors associating 
with snRNAs. 
 
 
 
 
 
 
A 
B 
Figure 14: Consensus 5’splice site of U2-type intron and intron 27 of MYH6: The 
Figure illustrates the cis-elements of intron required for splicing. Panel A correspond 
to splice sites regions which are recognized by various snRNAs in a U2-dependent 
intron. Panel B illustrates the cis-elements in intron 27 of MYH6 gene. WT 5’Splice 
site is shown along with 5’SS mutant, U12-type 5’SS mutant sequences and U125’SS 
CC/GG mutants. The letters in bold and underlined letters represent the mutated 
nucleotides. 
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Since, 5’ splice site binds to U1 and U6 snRNAs by Watson- Crick base pairing and these 
RNA-RNA interactions are phylogenitically conserved and essential for splicing to occur, 
we mutated the 5’ splice site of the intron 27 of the minigene reporter construct to 
eliminate the wild type site (Figure 14, panel B). The 5’ splice site was a mutated to 
consensus U12-type 5’ splice site (GUAUCCUU) and this mutant was called U125’SS 
mut. Firstly, we wanted to know if this mutant would splice, since branch site and 3’ 
splice site were wild-type (i.e. U2-dependent) and secondly which spliceosomal 
machinery (major or minor) would be used.  Mutations were also introduced in the 5’ 
splice site such that it is neither U2-type nor U12-type and the mutant was called 5’SS 
mut (CCGGGCUC). This mutant was constructed to completely eliminate the binding of 
U1 and U6 snRNAs to the splice site junctions and identify if the mutant would splice. 
The third mutation introduced was CC5/6GG mutation in the U125’SS mut to generate 
the U125’SS CC/GG mutant (referred as CC/GG mutant). Using this mutant, we wanted 
to know whether major or minor spliceosome, is splicing the MYH6 U125’SS mut. 
 
Since, it is known that wild-type splicing gets abolished and cryptic splicing is activated 
if CC5/6GG is mutated in U12-dependent intron F of p120 gene. Using this construct in 
Figure 15: In vivo splicing 
patterns of MYH6 intron 27 
5’ splice site mutants: 5’ 
splice site mutants were 
transfected in mammalian 
cells, RT-PCR was performed 
and analyzed for splicing. 
U12-type 5’SS mutant and 
U12 5’SS CC5/6GG mutant 
spliced products are similar to 
wild-type. However 5’SS 
mutant activates a cryptic 
splicing event.  
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vivo suppression system, developed for U12-dependent (p120 gene) intron, could be 
utilized (Hall and Padgett, 1996; Kolossova and Padgett, 1997; Incorvaia and Padgett, 
1998). All splice site mutants were transfected in CHO cells using polybrene and upon 
RNA isolation analyzed for spliced phenotypes. As expected, bands were not observed 
seen in case of mock (negative) control. Wild type (WT) spliced product is 263 bp long 
(Figure 15, lane 2).  U125’SS mutant (lane 4) which had consensus U12-type 5’ splice 
site showed phenotype similar to the wild type, suggesting either splicing takes place in 
mutant utilizing the minor spliceosomal pathway or there is no effect of mutation on the 
splicing. To answer this question, we utilized the CC5/6GG mutant (lane 5). RNA-RNA 
interactions between the snRNAs and pre-mRNA are the basis of splicing and any 
mutation in one of the interacting partners leads to inhibition of these interactions and 
hence affects splicing. It has been shown that CC at positions 5 and 6 in a U12-dependent 
intron are necessary for splicing to occur. If CC at 5 and 6 positions in a U12-dependent 
intron are mutated, splicing does not take place. However, MYH6 U12 5’SS CC5/6GG 
mutant spliced phenotype is similar to wild-type (Figure 15, lane 5). We co-transfected 
suppressor U11 and U6atac snRNAs along with U125’ SS CC5/6GG mutant since, 
suppressor snRNAs are known to restore splicing. U11 snRNA with a mutated GG6/7CC 
and U6atac snRNA with mutated GG14/15CC are called suppressor snRNAs as they 
restore the base pairing interactions with CC5/6GG in the U12 5’SS CC/GG mutant. 
However, the results obtained were quite ambiguous and could not be reproduced.  Upon 
careful analysis of the wild-type genomic sequence and U12 5’SS CC/GG, we found that 
both wild-type and CC/GG mutant have guanine (G) at the 5th position in intron 27. This 
observation suggested that G at 5th position could be important in splicing intron 27. This 
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observation was further supported by splicing phenotypes observed from in vivo spliced 
point mutants, G5A and G5C (Figure 22, lanes 8 and 9) where splicing was completely 
abolished (section 3.9). 
 The 5’SS mut which has 5’ splice site mutations (GTA 124/CCG) such that the 
splice site is completely mutated for splicing, cryptic splicing was activated. Spliced 
phenotype of 5’SS mut is smaller than the wild type (Figure 15, lane 3).  
 
 
 
 
The band was extracted from the gel, PCR product was eluted and its sequence was 
analyzed. Since in this mutant, the intronic 5’ splice site GT was mutated to CC hence the 
splice site no longer was U2 dependent, a cryptic 5’ splice site was utilized for the 
splicing of the intron. Spliced sequence analysis showed that there is a 50 nucleotide shift 
in 5’ splice site upstream of the normal splice site that produced smaller splice product 
Figure 16: Affect of 5’ splice site mutation: The Figure illustrates the comparison of 
WT (upper panel) and cryptic (lower panel) splicing of intron 27 of MTH6. Blue line 
indicates that cryptic splice site is located in the exon 27. Sequence similarity of both 
the sites recognized is shown in the lower panel. In the lower panel, region shown in 
blue represents exon 27 and region in black illustrates intron 27.  
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(Figure 16).  The upstream cryptic 5’ splice site is identical to the WT 5’ splice site which 
is CCAA/GT.  
 
3.7 In vitro Splicing Assay for Splice Site Mutants 
 To study the effect of 5’ splice site mutations on miRNA processing, we utilized 
the in vitro splicing assay system.  The splice site mutants were PCR amplified from exon 
27 to exon 28 including intron 27 containing miRNA and cloned in pUC 19 vector under 
T7 promoter. Plasmid DNA was linearized with Xba1 and the linear plasmid DNA was 
transcribed in vitro in presence of α-P32 radio-labeled UTP. Then in vitro splicing assay 
was performed in HeLa cell nuclear extracts as described in Chapter 2. Similar to miRNA 
stem-loop mutants, splice site mutants also failed to splice in vitro and, pre-miR208 along 
with Drosha cleaved mRNA products were detected (Figure 17). Anti U2 oligo to block 
U2-dependent splicing and to block U12 dependent splicing both anti-U2 oligo and anti-
U12 oligo were added. As mentioned in section 2.8, sequence of anti-U2 oligo is 
complementary to U2 snRNA nucleotides 27–49 (Dietrich et al, 1997) and sequence of 
anti-U12 oligo is complementary to U12 snRNA nucleotides 11–28 (Dietrich et al, 1997). 
We wanted to confirm if MYH6 U12 5’SS mutant construct splices using major or minor 
spliceosomal machinery for splicing. But since the MYH6 substrates (wild-type as well 
as the mutants) fail to splice in vitro system, we could not conclude if U125’SS mutant 
splices using major or minor spliceosomal machinery. However, precursor miR-208 
processed from wild type as well as 5’SS, U125’SS and U12 5’SS CC/GG mutants 
(Figure 17). It appears that miRNA processing can occur even if splice products are not 
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observed. MYH6 pre-mRNA is a good substrate for miRNA processing but a poor one 
for splicing.  
 
3.8 Quantitation of Mature miR-208 Expression in Splice Site and Stem-Loop 
Mutants 
  
 
Pre-
miR-
208 
A B 
Figure 17: In vitro spliced phenotypes of 5’ splice site mutants: Lane 1 and lane 9 
shows century marker and decade markers, lanes 2-5 show in vitro spliced wild-type 
MYH construct. Lanes 6-8 show 5’SS mutant. Panel B lanes 3-5 show U125’SS and 
lanes 6-8 show U125’SS CC/GG mutant. Anti-U2 indicates lanes to which anti-U2 
oligo was added and U12 indicates addition of anti-U12 oligo to block U2-dependent 
and U12-dependent splicing respectively. 
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 miRNA processing is a compartmentalized process and first step takes place in 
the nucleus where precursor miRNA is made and then second step occurs in cytoplasm 
where precursor is processed to mature miRNA (Lee et al, 2002; Kim and Kim, 2007).                              
In vitro splicing assay gave us some insight about the precursor miR-208 since it takes 
place in the nuclear extract. We detected only the spliced product by RT-PCR, mature 
miRNA could be detected in vivo by quantitative RT-PCR (real-time PCR or qRT-PCR) 
which is a sensitive and efficient method to detect small RNA species.  
 Mature miR-208 expression from stem-loop and the splice site mutants was 
detected using qRT-PCR. The relative expression of miR-208 is plotted as 2-∆∆Ct after 
normalizing to snoRNA202 and then to WT. miR-208 expression in case of loop mutant 
is expressed approximately 30 
folds as compared to the wild 
type (Figure 18). miR-208 
expression at such a high level from loop mutant could be due to any changes in the 
2-
∆
∆
C
t  
Figure 18: Quantitative 
RT-PCR expression of 
mature miR-208 from 
MYH6 stem-loop and 5’ 
splice site mutants: The 
Figure shows relative 
expression of miR-208 
expressed from various 
mutants. Relative 
expression is plotted as 2-
∆∆Ct after normalizing to 
sno202 expression levels 
and then to WT mir-208 
levels. 
CC/GG 
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secondary structure of miRNA or change in sequence at the terminal loop region could 
have caused such an increase. It is thought that the terminal loop region plays a very 
important role in miRNA processing (Kim and Kim, 2007). Figure 19 represents same 
graph as Figure 18 without comparing loop mutant as it becomes difficult to compare 
expression profile of miR-208 from other mutants with high level if expression from the 
loop mutant. The relative expression of miR-208 in all the mutants namely 5’SS, U12 
5’SS, U12 5’SS CC5/6GG (referred as MYH CC/GG in Figure 18 and 19) and UH 
mutant is reduced as compared to the wild type. All these mutants besides 5’SS mut show 
similar splicing phenotypes as the wild-type (Figures 13 and 15).    
 This indicated mutations in the 5’ splice site of the intron affect miRNA 
processing and also mutating the stem-loop structure of miRNA affect miRNA-
Figure 19: Quantitative RT-PCR expression of miR-208 from MYH6 stem-loop 
and 5’ splice site mutants: The figure shows relative expression of miR-208 
expressed from various mutant constructs. Relative expression is plotted as 2-∆∆Ct after 
normalizing to snoRNA202 expression levels and then to WT.  
2-
∆
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CC/GG 
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processing as well. Interestingly, U12 5’SS CC5/6GG almost failed to express miR-208 
showing that CC5/6 are important for miR-208 processing. These results suggest there is 
some interplay between the splice site and miRNA processing.  
 
3.9 In vivo Splicing Phenotypes of Point Mutants  
 Pictogram is a pictorial representation of analysis of nucleotides at a particular 
position in a DNA sequence. A pictogram representing the 5’ splice site sequence content 
of miRNA harboring introns was designed (Figure 20). Size of nucleotide at a position is 
proportional to its conservation for example; A is more conserved at position 3 than G.  
Based on this splicing sequence content, point mutations in intron 27 of minigene were 
made. The 5’ splice site of intron 27 of the myosin heavy chain was mutated at positions 
3 through 7 (Figure 21). If the 5’ splice site sequence of MYH intron 27 is compared with 
that of pictogram, considerable similarities and dissimilarities are seen. G and T at 
positions 1 and 2 respectively are completely conserved, indicating their evolutionary 
importance and could possibly have a role in pre-mRNA splicing and miRNA processing. 
Purines are largely present at positions 3-7. AAG at positions 3-5 are conserved as well, 
MYH CC/GG 
Figure 20: Pictogram representing 5’ splice site of 15 miRNA coding introns: -1 
to -17 represent the sequence at exonic splice site junction and 1 to 17 represent the 
bases in the intron and -1 to -17 represent the 5’ exon. Bigger size of base at a 
position corresponds to higher conservation. 
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however GCA can be present in some cases (Figure 20). Positions 6 and 7 are quite 
degenerate with lack of C and T at 6th and 7th position respectively.    
 As mentioned before, the 5’ splice site of MYH intron 27 was mutated based on 
sequence conservation of miRNA coding introns. Mutant G3A had a mutation from G to 
A at position 3 since A is more dominant than G at the position (Figure 21). At position 
4, base A is present in majority of introns studied, although C is found as well; intron 27 
also has A at 4 position so we mutated A at 4 position to C and called it A4C mutant and 
in A4G mutant mutated A at 4 position to G keeping in mind that G is not present in 
miRNA coding introns. Similarly G5A and G5C mutants were made for 5th position 
where A is rarely present and C is not present as per pictogram. Pyrimidine C is not 
present at 6th position in the pictogram, however it is present in MYH intron 27 so C6G 
and C6T mutants were made for position 6. For the 7th position T7A and T7G mutants 
were made by comparing intron 27 with the pictogram.  
 
 
 
  
 All point mutants were transfected in CHO cells using polybrene, RNA was 
isolated after 36 hours and analyzed for spliced phenotypes. As expected, spliced and 
Figure 21: Intron 27 of MYH showing 5’ splice site point mutations: Upstream and 
downstream exons are shown in orange boxes and miR-208 is shown in the intron. 
Numbers 1-8 represent the positions of bases in the intron. Introduced mutations are 
indicated by the dashed lines. For example, G at position 5 is mutated to A and mutant 
is called G5A, another mutant G5C has a mutation from G to C at 5th position.  
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unspliced product bands were not found in negative controls (Figure 22, lanes 2 and 3). 
Both unspliced and spliced products were observed in the wild type as well as in the 
mutants. The wild-type spliced product is 263 bp long (Figure 22, lane 4). G3A mutant 
appears to splices better than the wild-type (lane 5).  
Figure 22: In vivo splicing patterns of 5’ splice site point mutants: Point mutants 
were transfected in mammalian cells, RT-PCR was performed using the F2 and R2 
primers. Panel A illustrates the affect of point mutations at positions 3 through 7 in the 
5’ splice site of intron 27 on splicing in vivo. Panel B depicts quantitation of relative 
splicing among the point mutants. 
A 
B 
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This could be due to the fact that in adenosine is a preferred base at position 3 than G 
(though it is present in some introns). Splicing goes down in case of 4’ position mutants 
(lanes 6 and 7) since adenosine is again a preferred base at the 4th position and C is seen 
in some introns coding miRNA. If we mutate A to C, splicing decreases but if A is 
mutated to G a further reduction in splicing is seen. In case of 5’ position where guanine 
is the preferred nucleotide and was mutated to A (lane 8) and C (lane 9) negligible 
splicing was seen, indicating the importance of G at 5th position. As shown in the 
pictogram, positions 6 and 7 are quite degenerate and flexible for nucleotides, mutating C 
and T at 6th and 7th position respectively did not abolish splicing. However, splicing with 
6th position mutants was as good as the wild-type (Figure 22, lanes 10 and 11). Splicing 
was little reduced as compared to the wild-type in the 7th position mutants as nucleotides 
A and G are also found at this position. The spliced and unspliced products obtained with 
the 4th and 5th position mutants (A4C, A4G, G5A and G5C) do not correspond to the total 
spliced and unspliced product quantity as the wild-type and other mutants. It is possible 
that splice site junction recognized by the spliceosome is upstream or downstream of the 
F2 and R2 primers and therefore, could not be amplified and detected. There is another 
possibility that the region of exons 27 and 28 was skipped during splicing and hence 
spliced and unspliced products were not observed. 
 
 3.10 Quantitation of Mature miR-208 Expression in Point Mutants 
 qRT-PCR was performed on the same RNA that was used for in vivo splicing 
phenotype analysis for the 5’splice site point mutants so that miRNA expression could be 
compared with relative splicing. The relative expression of mature miR-208 normalized 
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to snoRNA202 was calculated and a graph was plotted (Figure 23). miR-208 expression 
reduces in G3A mutant as compared to the wild type. The reduction in miRNA 
expression is more significant in the A4C, A4G and G5A mutants. This indicated adenine 
and guanine at 4th and 5th positions is not only important for splicing (Figure 22) but also 
for miRNA processing. miR-208 levels from C6G, C6T and T7A mutants were higher 
than wild type levels indicating these mutations in the splice site enhanced the processing 
of miRNA. The level of relative splicing in 6th and 7th position mutants is also better than 
wild type suggesting these mutations not only increase splicing but also miRNA 
processing. qRT-PCR and the in vivo splicing analysis using RT-PCR show that presence 
of some nucleotides at a certain position is more favorable for pre-mRNA splicing or pre-
miRNA processing to take place.  
 
Figure 23: Quantitative RT-PCR expression of miR-208 in point mutants: The 
figure shows relative expression of miR-208 plotted as 2-∆∆Ct after normalizing to 
snoRNA202 expression levels and then to miR-208 levels from the wild-type.  
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3.11 In vivo Splicing Phenotypes for U12-dependent miRNA System 
 p120 gene or human nucleolar proliferative antigen gene has a well identified 
U12-dependent intron, intron F, which has been characterized for both in vivo as well as 
in vitro splicing. Since no microRNA is known to exist in an U12-dependent intron, we 
were interested if U12-dependent intron would be compatible with miRNA processing if 
it is introduced in the intron upstream of branch site. Also we wanted to address if 
splicing of a U12-dependent intron would be affected by presence of miRNA. 
 We introduced a hsa-miR-208 encoding 137 bp fragment from intron 27 of 
MYH6 in the intron F of p120 minigene reporter construct (Figure 24). We also mutated 
the 5’ splice site region in intron F to identify the affects of these mutations and presence 
of miRNA on splicing and miRNA processing. It has been shown that if CC at 5th and 6th 
position in intron F of p120 minigene are mutated to GG a cryptic splicing event is 
activated as shown in Figure 25 (panel A) (Incorvaia and Padgett, 1998). It has also been 
shown that if U11 snRNA GG6/7CC and U6atac GG14/15CC are cotransfected with 
p120 intron F CC5/6GG mutations, it restores splicing as wild type. p120 minigene 
Figure 24: Intron F of p120 minigene showing introduced miR-208 and 
mutations: miR is represented by the stem-loop structure between 38 and 175 
nucleotides, branch point Adenosine is marked at 214th base. Mutated bases are 
shown in bolds.  
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construct and its mutants along with appropriate controls were transfected in CHO cells, 
isolated RNA and performed RT-PCR and the results are shown (Figure 25, panel B). 
Negative controls as expected did not show any bands (Figure 25, Panel B, lanes 2 and 
3). In vivo spliced p120 wild type showed spliced, cryptic and unspliced bands (Figure 
25, Panel B, lane 4). Lane 5 shows spliced variants for p120 CC5/6GG mutant where a 
cryptic splicing event takes place and hence spliced band was not observed. However, an 
increased level of unspliced product was also observed. 
 Splicing phenotypes for p120 miR-208 mutant are shown in lane 6 and in this 
Figure 25: In vivo splicing patterns of p120 mutants: p120 mutants and wild-type 
was transfected in mammalian cells and RT-PCR analysis was done for spliced 
phenotypes. Panel A illustrates the site of miR-208 introduction and sites where 
cryptic or wild-type splicing takes place. Panel B shows splicing phenotypes of the 
p120 mutants. Marked with arrows are spliced, cryptic spliced and unspliced bands. 
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case cryptic splicing does not take place and only spliced or unspliced products were 
detected. Unspliced product was only observed upon the in vivo splicing analysis of p120 
miR-208 5’SS and p120 miR-208 CC5/6GG mutants (Figure 25, panel B, lanes 7 and 8 
respectively). Introduction of the 5’ splice site mutations and/or introduction of miRNA 
in the intron completely abolished the splicing event. Co-transfection of U11 snRNA 
GG6/7CC and U6atac GG14/15CC snRNA with the p120 miR-208 CC5/6GG mutant 
(lane9) also did not rescue the splicing defect (as it does in p120 wild type, Incorvaia and 
Padgett, 1998).   
 
3.12 Quantitation of Mature miR-208 Expression in U12-dependent miRNA System 
 qRT-PCR was performed on the same RNA that was used for in vivo splicing 
phenotype analysis for the p120 miR-208 wild type and splice site mutants so that 
Figure 26: Quantitative RT-PCR expression of miR-208 in p120 system: The 
figure shows relative expression of miR-208 expressed from p120 minigene system, 
plotted as 2-∆∆Ct after normalizing to sno202 expression levels and then to miR-208 
levels from the p120miR construct.  
2-
∆
∆
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miRNA expression could be compared with relative splicing. The relative miR-208 
expression normalized to sno202 and then to p120 miR is plotted (Figure 26).  Since, 
microRNA is not known to exist in a U12-dependent intron; we were interested in finding 
if microRNA would be processed from U12-dependent intron. miR-208 expression for 
p120 miR208 CC5/6GG mutant is approximately 11 folds the level of p120 miR208 wild 
type and it is about 10 folds for p120 miR208 5’ SS mutant (Figure 26). But if these 
results are compared with the in vivo splicing results (Figure 25), we do not observe a 
positive co-relation between the two processes as splicing is completely abolished in 
these mutants; however, miRNA processing is better than the wild type. It apparently 
appears that Drosha (microprocessor) is actively processing the miRNA to its precursor 
but splicing is not taking place. It could be due to the fact that the splicing machinery and 
miRNA processing machinery cannot act together in a U12-dependent intron. If this is 
the case then which component of spliceosome is of utmost importance and what does 
microprocessor and spliceosome share in common remains unanswered.  
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
4.1 Conclusions 
 Using the MYH6 minigene construct, we were able to utilize CHO cell-based 
transient transfection system to study pre-mRNA splicing and miRNA processing. miR-
208 expresses from the intron 27 of MYH6 gene, in the heart and tracely in lungs. Our 
results show that MYH 6 expresses in heart, kidney, lung, sparsely in brain but none in 
liver, indicating miR-208 expression is tissue-specific or regulated post-transcriptionally 
as MYH6 expresses in kidneys and lungs where miR-208 does not express. There could 
be some additional factors that are required for miR-208 expression, which are present in 
heart and lungs, aiding in its efficient processing. Since, miR-208 is located intronically, 
effect of miR sequence (and structure) on pre-mRNA splicing was studied. Mutations in 
the predicted stem-loop structure of miR-208 do not affect pre-mRNA splicing. But since 
the mutations were introduced in the predicted stem-loop regions of miR-208, namely, 
lower helix, upper helix and loop regions, the effect on miR expression level was 
expected. The in vitro splicing assay in cell-free extract using the stem loop mutants 
showed that the MYH6 pre-mRNA is a poor substrate for in vitro splicing but gave some 
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insight on miRNA processing. Pre-miR-208 was detected in the wild-type and loop 
mutants but it was not detected in upper helix and lower helix mutants suggesting 
importance of the helical regions in miRNA processing. We performed the quantitative 
RT-PCR to detect the expression levels of mature miR-208 from these mutants.    
Expression of miR-208 from loop mutant is approximately 30 folds compared to the wild 
type, on the other hand, its expression from upper helix mutant reduced 5 folds. Since, 
miR-208 is intronically located, splice site sequences could also influence miRNA 
processing so the 5’ splice site region of intron 27 (intron harboring miR-208) was 
mutated. In vivo splicing showed that the U12 5’SS mutant and CC5/6GG mutant splice 
similar to the wild-type but 5’SS mutant activated a cryptic splicing event. DNA 
sequencing on the PCR product revealed that splicing takes place from a site located in 
the exon 27. The sequence is located 50 nucleotides upstream of wild-type site and is 
identical to the wild-type sequence. Level of mature miR-208 expression was detected by 
qRT-PCR studies and was reduced as compared to the wild-type levels. miR-208 
expression from 5’SS was reduced approximately 5 folds as compared to the wild-type 
and negligible from the CC5/6GG mutant. To study how flexible and permissive is the 5’ 
splice site to allow miRNA processing and splicing to occur, point mutations were 
introduced in 5’ splice site of intron 27. G3A mutant splices better than the wild-type and 
miR-208 levels are comparable to the wild type. This could be due to the fact that in 
adenosine is a preferred base at position 3 than G (though it is present in some introns). 
Splicing goes down in case of 4’ position mutants (A4C and A4G) since adenosine is 
again a preferred base at the 4th position and C is seen in some introns coding miRNA. If 
A is mutated to C, splicing decreases but if A is mutated to G a further reduction in 
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splicing is seen. About 2 folds reduction in miR-208 expression was observed with both 
A4C and A4G mutants. In case of 5’ position where guanine is the preferred nucleotide 
and was mutated to A or C, negligible splicing was detected, indicating the importance of 
G at 5th position. About 2 folds decrease in miR-208 expression was detected fir G5A 
mutant; however, level of expression for G5C mutant was comparable to the wild-type. 
Positions 6 and 7 are quite degenerate and flexible for nucleotides, mutating C and T at 
6th and 7th position respectively did not abolish splicing. However, splicing with 6th 
position mutants (C6G and C6T) was as good as the wild-type but miR-208 expression 
from both mutants was better than the wild type. Splicing was little reduced as compared 
to the wild-type in the 7th position mutants since nucleotides A and G are also found at 
this position in some miRNA containing introns. T7A expressed miR-208 about 1.7 folds 
compared to the wild-type, on the other hand, 2 folds decrease was observed in T7G 
mutant. It appears that G, A and G are required at 3rd, 4th and 5th positions respectively for 
both pre-mRNA splicing and miR-208 processing to occur. Till now, miRNAs have been 
detected in U2-dependent introns but none in U12-dependent introns. After introduction 
of miR-208 in intron F (U12-dependent) of p120 minigene and mutating 5’ splice site of 
intron F, in vivo splicing and qRT-PCR analysis was done. We observed that p120 with 
miR-208 splices but its mutants (5’SS and CC5/6GG) failed to splice. However, miR-208 
expression was 3 and 4 folds in CC5/6GG and 5’SS mutants respectively as compared to 
the p120 with miR-208. We did not observe a positive co-relation between the two 
processes as splicing is completely abolished in these mutants; however, miRNA 
processing is better than the wild type. It appears that Drosha (microprocessor) is actively 
processing the miRNA but splicing is not taking place if miR-208 is present in minor 
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class intron in case of the p120 miR-208 CC5/6GG and p120 miR-208 5’SS mutants. It 
could be due to the fact that the splicing machinery and miRNA processing machinery 
cannot act together in U12-dependent intron where miR-208 has been incorporated and 5’ 
splice site has been mutated. 
 
4.2 Future Directions 
     We want to establish if miRNA processing and splicing in both, U2-dependent 
or U12-dependent intron are inter-linked. It can be proven by the in vitro splicing assay in 
cell-free extracts. In vitro splicing assay also aids to determine various intermediates and 
hence understand basic mechanism coupling the two processes. Since the MYH6 
substrate used before was splicing deficient, a new construct which would enable 
studying miRNA processing and pre-mRNA splicing is required. It can be achieved by 
introduction of certain cis-element sequences essential for splicing. We have detected the 
mature miR-208 expression levels in wild type as well as the mutants, but precursor miR-
208 levels can also be detected using qRT-PCR. We want to develop an in vivo 
suppression assay system for intron 27 of MYH6 minigene. We would utilize the in vivo 
suppression assay system for intron F of p120 minigene and suppress splicing in 
CC5/6GG mutant using the U11 and U6atac snRNA suppressors. Finally, we would 
identify the protein/factor involved if pre-mRNA splicing and miRNA processing are 
coupled. 
 
 
 
63 
 
BIBLIOGRAPHY 
 
1. Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. 
Cell, 116(2): 281-97. 
2. Baskerville, S. and Bartel, D.P. (2005). Microarray profiling of microRNAs reveals 
frequent coexpression with neighboring miRNAs and host genes. RNA, 11: 241–247. 
3. Bentwich, I. (2005). Prediction and validation of microRNAs and their targets. FEBS 
Letters, 579: 5904–5910. 
4. Black, D.L. (2003). Mechanisms of alternative pre-messenger RNA splicing. Annual 
Reviews of Biochemistry, 72(1): 291–336. 
5. Bohnsack, M.T., Czaplinski, K., Gorlich. D. (2004). Exportin 5 is a Ran-GTP-
dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. 
RNA, 10: 185–191. 
6. Borchert, G.M., Lanier, W., Davidson, B.L. (2006). RNA polymerase III transcribes 
human microRNAs. Nature Structural and Molecular Biology, 13: 1097–1101.  
7. Brain, S.D., Williams, T.J., Tippins, J.R., Morris, H.R., MacIntyre, I. (1985). 
Calcitonin gene related protein is a potent vasodilator. Nature, 313(5997): 54-56. 
8. Breathnach, R., Benoist, C., O’Hare, K., Gannon, F., Chambon, P. (1978). Ovalbumin 
gene: evidence for a leader sequence in mRNA and DNA sequences at the exon-
intron boundaries. PNAS, 75: 4853–4857. 
9. Cai, X., Hagedorn, C.H., Cullen, B.R. (2004). Human microRNAs are processed from 
capped, polyadenylated transcripts that can also function as mRNAs. RNA, 10: 1957–
1966. 
64 
 
10. Callis, T.E., Pandya, K., Seok, H.Y., Tang, R.H., Tatsuguchi, M., Huang, Z.P., Chen, 
J.F., Deng, Z., Gunn, B., Shumate, J., Willis, M.S., Selzman, C.H., Wang, D.Z. 
(2009). MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in 
mice. J. Clin. Invest., 119(9): 2772-2786. 
11. Chen, C.Y., Gherzi, R., Ong, S.E., Chan, E.L., Raijmakers, R., Pruijn, G.J.M., 
Stoecklin, G., Moroni, C. (2001). AU binding proteins recruit the exosome to degrade 
ARE-containing mRNAs. Cell, 107(4): 451–464. 
12. Chomczynski, P. and Sacchi, N. (1987). Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-9. 
13. Copp, D.H. and Cheney, B. (1962). Calcitonin-a hormone from the parathyroid which 
lowers the calcium-level of the blood. Nature, 193: 381-2.  
14. Cullen, B.R. (2004). Transcription and processing of human microRNA precursors. 
Mol. Cell, 16: 861–865. 
15. Dietrich, R.C., Incoravia, R., Padgett, R.A. (1997). Terminal intron dinucleotide 
sequences do not distinguish between U2- and U12-dependent introns. Mol. Cell, 1: 
151–160. 
16. Friedman, R.C., Farh, K.K.H., Burge, C.B., Bartel, D.P. (2009). Most mammalian 
mRNAs are conserved targets of microRNAs. Genome Research, 19(1): 92–105. 
17. Griffiths-Jones, S., Saini, H.K., van Dongen, S., Enright, A.J. (2008). miRBase: tools 
for microRNA genomics. Nucleic Acids Res., 36: 154-158. 
18. Grunstein, M. (1997). Histone acetylation in chromatin structure and transcription. 
Nature, 389: 349-352.  
65 
 
19. Hall, S.L. and Padgett, R A. (1996). Requirement of U12 snRNA for in vivo splicing 
of a minor class of eukaryotic nuclear pre-mRNA introns. Science, 271: 1716–1718. 
20. Hall, S.L., and. Padgett, R.A. (1994). Conserved sequences in a class of rare 
eukaryotic nuclear introns with non-consensus splice sites. J. Mol. Biol., 239: 357–
365. 
21. Hartwell, L.H., Hood, L., Goldberg, M.L., Reynolds, A.E., Silver, L.M., Veres, R.C. 
(2004). Genetics: From genes to genomes, 5th Edition. 
22. Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., 
Yatabe, Y., Kawahara, K., Sekido, Y., Takahashi, T. (2005). A polycistronic 
microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances 
cell proliferation. Cancer Research, 65: 9628-9632. 
23. Hirsch, P.F., Gauthier, G.F., Munson, P.L. (1963). Thyroid hypocalcemic principle 
and recurrent laryngeal nerve injury as factors affecting the response to 
parathyroidectomy in rats. Endocrinology, 73: 244–252. 
24. Incorvaia, R. and Padgett, R.A., (1998). Base pairing with U6atac snRNA is required 
for 5’ splice site activation of U12-dependent introns in vivo. RNA, 4: 709–718. 
25. Jackson, I.J. (1991). A reappraisal of non-consensus mRNA splice sites. Nucleic 
Acids Res., 19: 3795–3798. 
26. Kandels-Lewis, S. and Seraphin, B. (1993). Role of U6 snRNA in 5’ splice site 
selection. Science, 262: 2035-2039. 
27. Kataoka, N. and Ohno, F.M. (2009). Functional association of the microprocessor 
complex with the spliceosome. Mol. Cell Biol., 29(12): 3243-54. 
66 
 
28. Ketting, R.F., Fischer, S.E., Bernstein, E., Sijen, T., Hannon, G.J., Plasterk, R.H. 
(2001). Dicer functions in RNA interference and in synthesis of small RNA involved 
in developmental timing in C. elegans. Genes Dev., 15: 2654– 2659. 
29. Kim, V.N. and Nam, J.W. (2006). Genomics of microRNA. Trends Genet., 22: 165–
173. 
30. Kim, V.N. (2005). Small RNAs: classification, biogenesis, and function. Mol. Cell, 
19: 1–15. 
31. Kim, Y.K. and Kim, V.N. (2007). Processing of intronic microRNAs. EMBO J., 26: 
775–783. 
32. Kolossova, I. and Padgett, R.A. (1997). U11 snRNA interacts in vivo with the 5’ 
splice site of U12-dependent (AU-AC) pre-mRNA introns. RNA, 3: 227–233. 
33. Konarska, M.M. and Sharp, P.A. (1987). Interactions between small nuclear 
ribonucleoprotein particles in formation of spliceosomes. Cell, 49: 763-774. 
34. Konarska, M.M., Padgett, R.A., Sharp, P.A. (1985). Trans splicing of mRNA 
precursors in vitro. Cell, 42(1): 165-171. 
35. Lagos-Quintana, M., Rauhut, R., Lendeckel, W., Tuschl, T. (2001) Identification of 
novel genes coding for small expressed RNAs. Science, 294: 853−858. 
36. Laios, A., O'Toole, S., Flavin, R., Martin, C., Kelly, L., Ring, M., Finn, S.P., Barrett, 
C., Loda, M., Gleeson, M., D'Arcy, T., McGuinness, E., Sheils, O., Sheppard, B., O' 
Leary, J. (2008). Potential role of miR-9 and miR-223 in recurrent ovarian cancer. 
Molecular Cancer, 7: 35. 
37. Lee, R.C. and Ambros, V. (2001). An extensive class of small RNAs in 
Caenorhabditis elegans. Science, 294: 862−864. 
67 
 
38. Lee, R.C., Feinbaum, R.L., and Ambros, V. (1993). The C. elegans heterochronic 
gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75: 
843–854. 
39. Lee, Y., Ahn, C., Han, J., Choi, H., Kim,J., Yim, J., Lee, J., Provost, P., Radmark, O., 
Kim, S., Kim, V.N. (2003). The nuclear RNase III Drosha initiates microRNA 
processing. Nature, 425: 415–419. 
40. Lee, Y., Jeon, K., Lee, J.T., Kim, S., Kim, V.N. (2002). MicroRNA maturation: 
stepwise processing and sub-cellular localization. EMBO J., 21: 4663–4670. 
41. Lee, Y., Kim, M., Han, J., Yeom, K.H., Lee, S., Baek, S.H., Kim, V.N. (2004). 
MicroRNA genes are transcribed by RNA polymerase II. EMBO J., 23: 4051– 4060. 
42. Li, Q., Peterson, K.R., Fang, X., Stamatoyannopoulos, G. (2002). Locus control 
regions. Blood, 100: 3077-3086. 
43. Li, Q.L., Zhou, B., Powers, P., Enver, T., Stamatoyannopoulos, G. (1990). Beta-
globin locus activation regions: conservation of organization, structure, and function. 
PNAS, 87: 8207-8211. 
44. Madhani, H.D. and Guthrie, C. (1994). Dynamic RNA-RNA interactions in the 
spliceosome. Annu. Rev. Genet., 28: 1-26. 
45. Montzka, K.A. and Steitz, J.A. (1988). Additional low-abundance human small 
nuclear ribonucleoproteins: U11, U12. PNAS, 85: 8885–8889. 
46. Moore, M.J., Query, C.C., Sharp, P.A. (1993). Splicing of precursors to mRNA by 
the spliceosome in R.F. Gesteland and J.F. Atkins (ed.) "The RNA World" (Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, NY), pp 303-358. 
68 
 
47.  Morkin, E. (2000). Control of cardiac myosin heavy chain expression. Microsc. Res. 
Tech., 50(6): 522-531.  
48. Nilsen, T.W. (1993). Trans-splicing of nematode premessenger RNA. Annu. Rev. 
Microbiol., 47: 413-40.  
49. Nilsen, T.W. (1996). A Parallel Spliceosome. Science, 273: 1813. 
50. Nilsen, T.W. (1998). RNA structure and function, RNA-RNA interactions in nuclear 
pre-mRNA splicing, eds. Simons, R.W., Grunberg-Manago, M., (Cold Spring Harbor 
Laboratory Press, Cold Spring Harbor, NY), pp 279–307. 
51. Poy, M.N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P.E., 
Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., Stoffel, M. (2004). A pancreatic 
islet-specific microRNA regulates insulin secretion. Nature, 432: 226-230. 
52. Poy, M.N., Hausser, J., Trajkovski, M., Braun, M., Collins, S., Rorsman, P., Zavolan, 
M., Stoffel, M. (2009). miR-375 maintains normal pancreatic alpha- and beta-cell 
mass. PNAS, 106(14):5813-8. 
53. Proudfoot, N.J., Furger, A., Dye, M.J. (2002). Integrating mRNA processing with 
transcription. Cell, 108: 501-512. 
54. Richards, A., Luccarini, C., Pope, F.M. (1997). The structural organization of 
LAMA4, the gene encoding laminin alpha4. Eur. J. Biochem., 248: 15–23. 
55. Rodriguez, A., Griffiths-Jones, S., Ashurst, J.L., Bradley, A. (2004). Identification of 
mammalian microRNA host genes and transcription units. Genome Res., 14: 1902–
1910. 
56. Sharp, P.A. (1985). On the Origin of RNA Splicing and Introns. Cell, 42: 397-400. 
69 
 
57. Shatkin, A.J. and Manley, J.L. (2000). The ends of the affair: Capping and 
polyadenylation. Nat. Struct. Biol., 7: 838-42. 
58. Sikand, K., Slane, S.D., Shukla, G.C. (2009). Intrinsic expression of host genes and 
intronic miRNAs in prostate carcinoma cells. Cancer Cell Int., 9: 21. 
59. Siliciano, P.G. and Guthrie, C. (1988). 5’ splice site selection in yeast: Genetic 
alterations in base pairing with U1 reveal additional requirements. Genes and Dev., 2: 
1258–1267. 
60. Sperling, J., Azubel, M., Sperling, R. (2008). Structure and function of the pre-
mRNA splicing machine. Structure, 16: 1605-1615. 
61. Staley, J.P. and Guthrie, C. (1998). Mechanical devices in the spliceosome: Clocks, 
motors, springs and things. Cell, 92: 315-326. 
62. Sutton, R.E. and Boothroyd, J.C. (1986). Evidence for trans splicing in trypanosomes. 
Cell, 47(4): 527-35  
63. Takahashi, S., Onodera, K., Motohashi, H., Suwabe, N., Hayashi, N., Yanai, 
N., Nabesima, Y., Yamamoto, M. (1997). Arrest in primitive erythroid cell 
development caused by promoter-specific disruption of the GATA-1 gene. J. Biol. 
Chem., 272(19): 12611-5. 
64. Tang, G.Q. and Maxwell, E.S. (2008). Xenopus microRNA genes are predominantly 
located within introns and are differentially expressed in adult frog tissues via post-
transcriptional regulation. Genome Res., 18: 104–112. 
65. Tarn, W.Y. and Steitz J.A. (1996 (b)).  Highly diverged U4 and U6 small nuclear 
RNAs required for splicing rare AT-AC introns. Science, 273: 1824– 1832. 
70 
 
66. Tarn, W.Y. and Steitz, J.A. (1996 (a)). A novel spliceosome containing U11, U12, 
and U5 snRNPs excises a minor class (AT-AC) intron in vitro. Cell, 84: 801–811. 
67.  Tay, Y.M.S., Tam, W.L., Ang, Y.S., Gaughwin, P.M., Yang, H., Wang, W., Liu, R., 
George, J., Ng, H.H., Perera, R.J., Lufkin, T., Rigoutsos, I., Thomson, A.M., Lim, B. 
(2008). MicroRNA-134 modulates the differentiation of mouse embryonic stem cells, 
where it causes post-transcriptional attenuation of nanog and LRH1. Stem Cells, 
26(1): 17 -29. 
68. Tycowski, K.T., Kolev, N.G., Conard, N.K., Fok, V., Steitz, J.A. (2006). The ever-
growing world of small nuclear ribonucleoproteins. In The RNA World, Third 
Edition, R.F. Gesteland, T.R. Cech, and J.F. Atkins, eds. (Cold Spring Harbor, New 
York: Cold Spring Harbor Laboratory Press), pp. 327–368. 
69. vanRooij, E., Liu, N., Olson, E.N. (2008). MicroRNAs flex their muscles. Trends 
Genet., 24(4): 159-66. 
70.  vanRooij, E., Sutherland, L.B., Qi, X., Richardson, J.A., Hill, J., Olson, E.N. (2007). 
Control of stress-dependent cardiac growth and gene expression by a microRNA. 
Science, 316(5824): 575-9. 
71. Wang, Q., Li, Y.C., Wang, J., Kong, J., Qi, Y., Quigg, R.J., Li, X. (2008). miR-17-92 
cluster accelerates adipocyte differentiation by negatively regulating tumor-
suppressor Rb2/p130. PNAS, 105(8): 2889–2894. 
72. Weiss, A. and Leinwand, L.A. (1996). The mammalian myosin heavy chain gene 
family. Ann. Rev. of Cell Biol., 12: 417-39.  
73. Will, C.L. and Luhrmann, R. (2001). Spliceosomal UsnRNP biogenesis, structure and 
function. Curr. Opin. Cell Biol., 13: 290–301. 
71 
 
74. Will, C.L. and Luhrmann, R. (2006). Spliceosome structure and function. In The 
RNA World, Third Edition, R.F. Gesteland, T.R. Cech, and J.F. Atkins, eds. (Cold 
Spring Harbor, New York: Cold Spring Harbor Laboratory Press), pp. 369–400. 
75. Wu, J.A. and Manley, J.L. (1989). Mammalian pre-mRNA branch site selection by 
U2 snRNP involves base pairing. Genes Dev., 3: 1553-1561. 
76. Yi, R., Qin, Y., Macara, I.G., Cullen, B.R. (2003). Exportin-5 mediates the nuclear 
export of pre-microRNAs and short hairpin RNAs. Genes Dev., 17: 3011–3016. 
77. Ying, S.Y. and Lin, S.L. (2009). Intron-mediated RNA interference and microRNA 
biogenesis. Methods Mol. Biol., 487: 387-413. 
78. Ying, S.Y., Chang, C.P., Lin, S.L. (2010). Intron-mediated RNA interference, 
intronic microRNAs, and applications. Methods Mol. Biol., 629: 205-37.  
79. Zhuang, Y. and Weiner, A.M. (1986). A compensatory base change in U1 snRNA 
suppresses a 5’ splice site mutation. Cell, 46: 827–835. 
 
 
 
 
 
 
 
 
 
 
72 
 
APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1: Vector Map pCDNA3.1- : It has ampicillin (Amp) 
as selection marker for E.Coli and Neomycin as selection in 
mammalian cells. It has a human cytomegalovirus (CMV) 
promoter. The multiple cloning site showing restriction enzyme 
sites is represented. Genomic region from exon 26 to 29 including 
introns from MYH 6 gene was cloned between Xba1 and Bam H1 
sites. 
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GAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCC
GGGGGAAGCTCTCTTATACCCAGCAAATGGAGGACCTCAAAAGGCAGCTGGAGG
AGGAGGGCAAGgtgaggcccagtggggagggtgggcaggcttgatggcagccct
ggggcaattcatctcagtgccagaaatggagcctggagctggaaagagtcctct
gcaagggaaagaccctccagtctaggttctgccctgcagctaagcgtcatttaa
tgcctcttttcttattcgtaaggggatggggtgagcagactgggaaactcctca
aacagtgaggtgccacatcagcccacatggtgaataaggctgggcttggttgaa
gtactacataagaagagaatctagagaatggggcacagggagtccctcccacct
cctggtgcccccccccctccccagGCGAAGAACGCCCTGGCCCATGCACTGCAG
TCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAG
GCCAAGGCCGAGCTGCAGCGCGTCCTGTCCAAGGCCAACTCGGAGGTGGCCCAG
TGGAGGACCAAGTATGAGACGGACGCCATTCAGCGGACTGAGGAGCTCGAAGAG
GCCAAgtgagctccagatacccccttaacctgactctcagagaggaaggggcga
gaggacctggggtggggacaggcaaagtggtcatgagacggaagtggaagagac
aggaggaactcggagggcaacagaagtgcttggaagaaagcctgaactctttgc
tctgtgaactctggctggccctgacccacttcctgtgacgggcgagcttttggc
ccgggttatacctgatgctcacgtataagacgagcaaaaagcttgttggtcaga
ggagctaccgtcgatcagcctgtgtggggggtgagggcagggggcactgacacc
cagatgccactgcaggtagggaggacgcctgggcagcccgtgctggcggactct
gttccaggcatgagcaggctcagctcctgctaggctggacttacggtgtctcaa
ggagatatagggagggggtggaaggaggtccacccaaggctccagtgttgccca
gtagagtcacacacacaccctccaccctcacctgggcagAAAGAAGCTGGCCCA
GCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAAGTGCTCCTC
ACTGGAGAAGACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGA
CGTAGAGCGCTCCAATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGAAACTT
TGACAAGgtggaccatgggcgggggccgcagccagcatgcagggcaagggggca
tgaggggttcagtgagaggccaaaggcaacctccttggaggtggaggaggaggg
ctaagcccaggctcgggaccagggacagatcttggacatgcggctgaggctggg
ggctggggcactgggaagcaggagggctggggagctaaggctggggggctgaag
agtgagccttgtccccgggcagATCCTGGCCGAGTGGAAGCAGAAGTATGAGGA
GTCGCAGTCTGAGCTGGAGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGA
GCTCTTCAAGCTCAAGAACGCCTACGAGGAGTCCCTGGAGCACCTAGAGACCTT
CAAGCGGGAGAACAAGAACCTTCAGG 
Appendix 2: Sequence of MYH 6: The cloned genomic sequence of human 
Myosin Heavy Chain 6 gene. Exons are shown in bold and capital letters. 
Intronic sequences (intron 26-28) are shown in small letters. hsa-miR-208 is 
bolded in the intronic region and mature miRNA is underlined.  
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Appendix 3: Sequences of Primers: All primers are in 5’ to 3’ direction. 
 
 
 
1. MYH Xho F: GCCTCGAGGAGAGTTGGCCCGGCAG 
2. MYH BamH1 R: ACGGGATCCCCTGAAGGTTCTTGTTC 
3. F1: GGAAAAGGAGGCGCTAATCT 
4. R1: GCGTCCGTCTCATACTTGGT 
5. F2: GGAGCAGTACGAGGAGGAGA 
6. R2: CGTCCACCATCAAGTCCTCT 
7. F3: GGCTGTTAATGCCAAGTGCT 
8. R3: TCGTAGGCGTTCTTGAGCTT 
9. Exon Junction F: GAGGGCAAGGCGAAGAAC 
10. Exon Junction R: GGCCAGGATCTTGTCAAAGT 
11. 208 5’SS F: GAGGCCAACCGGGCTCCAG 
12. 208 5’SS R: CTGGAGCCCGGTTGGCCTC  
13.  208 U12 5’SS F: GAGGCCAAGTATCCTTCAGATACCC 
14. 208 U125’SS R: GGGTATCTGAAGGATACTTGGCCTC  
15. 208 U12BS F: CACACACATCCTTAACCCTCACC 
16. 208 U12BS R: GGTGAGGGTTAAGGATGTGTGTG 
17. 208 LH F: CTGTGACGCCGCTCGAAAAGGCCCGGG 
18. 208 LH R: CCCGGGCCTTTTCGAGCGGCGTCACAG 
19. 208 UH F: GGCCCGGGAATATCCTGATGCT 
20. 208 UH R: AGCATCAGGATATTCCCGGGCC 
21. Loop mutant: 5’ CCCGGGTTATACCACTACGAGTCGTATAAGACGAG 
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22. 208 CC/GG primer: GAGGCCAAGTATGGTTCAG  
23. MYH T7BamH1: 
ATATGGATCCTAATACGACTCACTATAGGGGGAGCAGTACGAGGAGGAGA 
24. MYH Xba1 reverse: ACGGTCTAGACGTCCACCATCAAGTCCTCT 
25. GAPDH Forward: GGAGAAACCTGCCAAGTATGATG 
26. GAPDH Reverse: TGAAGTCGCAGGAGACAACCT 
27. P120_Not repair: GAGGAAGGCGGCCGCGAGAGGG 
28. P120_Pme Repair: GAGAGGGGTTTAAACGCCTTAG 
29. Mir208 pri not Forward: GAATGCGGCCGCTGAACTCTGGCTGGCCCTGA  
30. Mir208 pri pme Reverse: GCATGTTTAAACCACACAGGCTGATCGACGGT 
31. P120 5’SS mut: GATGGAGCAGGATGAGTTTGCAGGGCAGAG 
32. P120 CC5/6GG mut: TGGAGCAGGATATGGTTGCAGGGCAGAG  
33. G3A: CCAAGTAAGCTCC 
34. G3C: CCAAGTCAGCTCC 
35. A4C: CAAGTGCGCTCCA 
36. A4G: CAAGTGGGCTCCA 
37. G5A: AAGTGAACTCCAG 
38. G5C: AAGTGACCTCCAG 
39. C6G: AGTGAGGTCCAGA 
40. C6T: AGTGAGTTCCAGA 
41. T7A: GTGAGCACCAGAT 
42. T7G: GTGAGCGCCAGAT 
